Document:

EX-10.31

 Exhibit 10.31 

Execution Version 
 CONSENT
AND AMENDMENT AGREEMENT 
 This Consent and Amendment Agreement (this “Agreement”), dated as of
March 8, 2013, is entered into by and among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such
capacity, and together with its successors and permitted assigns, “Agent”). 
 WHEREAS, pursuant to that
certain Loan and Security Agreement, dated as of March 30, 2011, as amended by that certain Consent and Amendment Agreement, dated as of December 20, 2011, as further amended by that certain Consent and Amendment Agreement, dated as of
June 28, 2012, as further amended by that certain Consent and Amendment Agreement, dated as of October 9, 2012, as further amended by that certain Consent and Amendment Agreement, dated as of November 19, 2012, as further amended by
that certain Consent and Amendment Agreement, dated as of December 28, 2012, as further amended by that certain Consent and Amendment Agreement, dated as of January 18, 2013, as further amended by that certain Consent and Amendment
Agreement, dated as of February 20, 2013, and as further amended by that certain Consent and Amendment Agreement, dated as of March 1, 2013 (the “First March 2013 Consent and Amendment”, each among Borrower, Agent
and the financial institutions party thereto as lenders (the “Lenders”; the Loan and Security Agreement, as so amended and as it may have been and may be further amended, restated or otherwise modified from time to time, the
“Loan Agreement”), Agent and the Lenders have made certain loans and other financial accommodations to Borrower subject to the terms and conditions set forth therein; 

WHEREAS, Agent and Lenders agreed to postpone, pursuant to the terms of the First March 2013 Consent and Amendment, the required
payments of principal and interest for both the Initial Term Loan and the Subsequent Term Loan that would otherwise be due and payable pursuant to Section 2.3(b) of the Loan Agreement on the Scheduled Payment Date occurring on March 1,
2013 until March 8, 2013; 
 WHEREAS, Borrower has requested that Agent and Lenders consent to postpone, subject to the
satisfaction of certain conditions, the required payment of principal for both the Initial Term Loan and the Subsequent Term Loan that would otherwise be due and payable pursuant to Section 2.3(b)(ii) of the Loan Agreement on the Scheduled
Payment Dates occurring on March 1, 2013 (which was postponed until March 8, 2013 pursuant to the First March 2013 Consent and Amendment) and April 1, 2013 and allocate the payment of the amounts that would otherwise have been due and
payable on such dates equally to each of the remaining Scheduled Payment Dates; 
 WHEREAS, Borrower has further requested that Agent
and Lenders consent to the amendment of the Fifth Amended and Restated Certificate of Incorporation (the “Charter Amendment”) and the filing of the Sixth Amended and Restated Certificate of Incorporation (the
“Restated Charter” and, together with the Charter Amendment, the “March 2013 Charter Amendments”)), each anticipated to be dated on or about March 8, 2013, of the Borrower, which would otherwise
be prohibited pursuant to Section 7.11 of the Loan Agreement, to, among other things, effect a 10:1 stock split of the Borrower’s Series A Preferred Stock, amend certain rights of the Borrower’s Series A stockholders, authorize the
creation of Series A-1 Preferred Stock (the “Series A-1 Preferred Stock”) into which certain of the Borrower’s Series A Preferred Stock may be converted and authorize the creation of Series B-1 Preferred Stock (the
“Series B-1 Preferred Stock”), certain of which shares are to be sold to investors to provide working capital for the Borrower, into which certain promissory notes may be converted and to satisfy the conditions for the
postponement of the principal payments contemplated by this Agreement; and 

 WHEREAS, Agent and Lenders constituting all Lenders are willing to agree to such requests,
subject to and in accordance with the terms and conditions set forth in this Agreement, including the grant of a security interest in and lien on the intellectual property owned or licensed by the Loan Parties. 

NOW, THEREFORE, each of Borrower, Lenders and Agent hereby agrees as follows: 

1. Recitals; Definitions. The foregoing recitals, including all terms defined therein, are incorporated herein and made a part
hereof. All capitalized terms used but not otherwise defined herein have the meanings given such terms in the Loan Agreement. 
 2.
Consent. In accordance with Section 10.08 of the Loan Agreement, Agent and Lenders hereby consent (i) to the March 2013 Charter Amendments, the forms of which are attached hereto as Exhibit A and (ii) to the
postponement of the principal payments (but not the payment of interest or other Obligations) that would otherwise be due and payable pursuant to Section 2.3(b)(ii) of the Loan Agreement on the Scheduled Payment Dates occurring on March 1,
2013 and April 1, 2013 subject, with respect to this clause (ii), to satisfaction of the following requirements: 
 (a)
with respect to the Scheduled Payment Date occurring on March 1, 2013, provided that: 
 (i) all conditions
precedent hereunder shall be satisfied or waived in the sole discretion of Agent; 
 (ii) by its execution and delivery of
this Agreement, Borrower has agreed to make principal payments to Agent, for the ratable benefit of the Lenders, in equal consecutive payments (A) in respect of the Initial Term Loan of $95,693.78 and (B) in respect of the Second Term Loan
of $116,959.10, in each case on each Scheduled Payment Date, commencing on April 1, 2013; provided that the final principal payment for the Initial Term Loan shall be in the amount of $95,639.79 and for the Second Term Loan shall be in
the amount of $116,959.20; 
 (b) with respect to the Scheduled Payment Date occurring on April 1, 2013, provided
that: 
 (i) the principal payment otherwise due and owing on March 1, 2013 was postponed in accordance with clause
(a) above; and 
 (ii) no Default or Event of Default shall have occurred and be continuing; and 

(iii) all representations and warranties in Section 5 of the Loan Agreement shall be true and correct as of such date; and

 (iv) Borrower agrees to make principal payments to Agent, for the ratable benefit of the Lenders, in equal consecutive
payments (A) in respect of the Initial Term Loan of $101,010.10 and (B) in respect of the Second Term Loan of $123,456.79, in each case on each Scheduled Payment Date, commencing on May 1, 2013; provided that the final
principal payment for the Initial Term Loan shall be in the amount of $101,010.13 and for the Second Term Loan shall be in the amount of $123,456.80; and 

  
 2 

 (v) Agent shall have received a certificate from an authorized officer of
Borrower confirming the requirements of the foregoing clauses (ii), (iii) and (iv); and 
 (vi) on or before 1:00 pm New
York time on March 29, 2013, Borrower shall have delivered the Cash Balance Projection (as defined below), updated to reflect the actual cash balances for the periods ending March 8, 2013, March 15, 2013, March 22,
2013, and March 29, 2013 (each, a “Subject Period”) and certified by the president, chief executive officer or chief financial officer of Borrower demonstrating that the Borrower’s cash balances for each of the
Subject Periods is equal to or greater than the projected cash balance set forth in the Cash Balance Projection for the corresponding period. 

3. Amendments. Subject to the terms and conditions of this Agreement, the Loan Agreement is hereby amended as follows: 

(a) Section 3.1 is hereby amended by replacing the second paragraph thereof, which defined the “Collateral,” in
its entirety and replacing it with the following: 
 “All of such Loan Party’s personal property of every kind and nature whether
now owned or hereafter acquired by, or arising in favor of, such Loan Party, and regardless of where located, including, without limitation, all accounts, chattel paper (whether tangible or electronic), commercial tort claims, deposit accounts,
documents, equipment, financial assets, fixtures, goods, instruments, investment property (including, without limitation, all securities accounts), inventory, letter-of-credit rights, letters of credit, securities, supporting obligations, cash, cash
equivalents, any other contract rights (including, without limitation, rights under any license agreements), or rights to the payment of money, and general intangibles (including Intellectual Property, as defined in Section 3.3 below), and all
books and records of such Loan Party relating thereto, and in and against all additions, attachments, accessories and accessions to such property, all substitutions, replacements or exchanges therefor, all proceeds, insurance claims, products,
profits and other rights to payments not otherwise included in the foregoing (with each of the foregoing terms that are defined in the UCC having the meaning set forth in the UCC). 

Notwithstanding the foregoing, the grant of a lien and security interest herein shall not extend to and the term “Collateral” shall
not include: any license agreement for the use of another Person’s Intellectual Property as in effect on the date hereof (each, an “In-License”), but only to the extent that the granting of such security interest would
constitute a default under such In-License as in effect on the date hereof, and only to the extent that such prohibition or default is enforceable under applicable law (including, without limitation, Sections 9-406, 9-407 and 9-408 of the UCC);
provided that upon the termination or expiration of any such prohibition or default, such In-License shall automatically be subject to the security interest granted in favor of Agent hereunder and become part of the “Collateral” and
provided further that the “Collateral” shall include all proceeds, products, substitutions and replacements of any In-License described, above.” 

(b) Section 3.3 is hereby amended by replacing it in its entirety and replacing it with the following: 

  
 3 

 “The Collateral shall include all intellectual property of each Loan Party, which shall be
defined as any and all copyright, trademark, tradename, servicemark, patent, invention, design, design right, software and databases, license, trade secret, customer lists, know-how, and intangible rights of each Loan Party, any marketing rights of
each Loan Party, and any goodwill, applications, registrations, claims, products, awards, judgments, amendments, renewals, extensions, improvements and insurance claims related thereto (collectively, “Intellectual Property”) now or
hereafter owned or licensed by a Loan Party, together with all accessions and additions thereto, proceeds and products thereof (including, without limitation, any proceeds resulting under insurance policies). In order to perfect or protect
Agent’s security interest and other rights in Loan Party’s Intellectual Property, each Loan Party hereby authorizes Agent to file a patent security agreement, substantially in the form provided by Agent (“Patent Security
Agreement”) and/or a trademark security agreement, substantially in the form provided by Agent (“Trademark Security Agreement”) with the United States Patent and Trademark Office and a copyright security agreement,
substantially in the form provided by Agent (“Copyright Security Agreement” and together with the Patent Security Agreement and the Trademark Security Agreement, the “Intellectual Property Security Agreements”) with
the United States Copyright Office as each are applicable and required by Agent.” 
 4. Conditions. The foregoing is
subject to the following conditions: 
 (a) Agent shall have received a counterpart of this Agreement and the Intellectual
Property Security Agreements, each duly executed by each Loan Party; 
 (b) Agent shall have filed an amendment to the
Financing Statements in the applicable filing office for each Loan Party amending the collateral definition as set forth in this Agreement; 

(c) Agent shall have received budget and cash balance projection prepared in good faith and based upon reasonable assumptions
covering the weekly periods commencing with the week ending March 1, 2013 through and including the week ending May 17, 2013, in the form attached hereto as Exhibit B (the “Cash Balance Projection”), updated
to reflect actual cash balances through the period ending March 1, 2013; 
 (d) Borrower shall have delivered a
certificate of an authorized officer of Borrower, providing verification of an incumbency and attaching (i) Borrower’s board resolutions approving the transactions contemplated by this Agreement and (ii) Borrower’s organizational
documents; 
 (e) Borrower shall have converted Indebtedness owed to GE Capital Equity Investments, Inc. pursuant to
(i) that certain Convertible Promissory Note, dated December 28, 2011, in the face amount of $330,000, (ii) that certain Convertible Promissory Note, dated April 2, 2012, in the face amount of $330,000 and (iii) that certain
Convertible Promissory Note, dated June 28, 2012, in the face amount of $32,641, each into Series B-1 Preferred Stock pursuant to a note exchange agreement reasonably acceptable to GE Capital Equity Investments, Inc.; 

(f) Agent shall have received evidence reasonably satisfactory to Agent that Borrower has received not less than $1,325,000 in
unrestricted cash from the sale of the Series B-1 Preferred Stock, which amount includes the $45,000 funded to Borrower by certain investors, 

  
 4 

 
as required by the First March 2013 Consent and Amendment) and shall provide such further documents, information, certificates, records and filings as Agent may reasonably request; 

(g) the Borrower shall deliver, a full and complete copy of the March 2013 Charter Amendments, certified by the Secretary of
State of the State of Delaware promptly after such filings; 
 (h) Agent shall have received, in immediately available funds,
an amount equal to the accrued interest due and payable, pursuant to Section 2.3(b)(i), for the Scheduled Payment Date occurring on March 1, 2013; and 

(i) (i) No Default or Event of Default shall have occurred and be continuing, (ii) all representations and warranties in
Section 5 of the Loan Agreement shall be true and correct as of the date hereof, (iii) each condition set forth in this Section 4 of this Agreement shall have been satisfied, and (iv) Agent shall have received a certificate from
an authorized officer of Borrower confirming each of the foregoing. 
 5. Reaffirmation of Debt Documents. By executing and
delivering this Agreement, Borrower hereby (i) reaffirms, ratifies and confirms its Obligations under the Loan Agreement, the Notes and the other Debt Documents; (ii) agrees that this Agreement and the Intellectual Property Security
Agreements shall be “Debt Documents” under the Loan Agreement; and (iii) hereby expressly agrees that the Loan Agreement, the Notes and each other Debt Document shall remain in full force and effect following any action contemplated
hereby. 
 6. Reaffirmation of Grant of Security Interest in Collateral. Borrower hereby expressly reaffirms, ratifies and
confirms its obligations under the Loan Agreement, including its mortgage, grant, pledge and hypothecation to Agent for the benefit of Agent and each Lender, of the lien on and security interest in, all of its right, title and interest in, all of
the Collateral. 
 7. Confirmation of Representations and Warranties; Liens; No Default. Borrower hereby confirms that
(i) all of the representations and warranties set forth in the Debt Documents continue to be true and correct as of the date hereof, except to the extent such representations and warranties by their terms expressly relate only to a prior date
(in which case such representations and warranties shall be true and correct as of such prior date); (ii) there are no Defaults or Events of Default that have not been waived or cured; (iii) Agent has and shall continue to have valid,
enforceable and perfected first-priority liens, subject to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by Borrower to Agent, for the benefit of Agent and each Lender, pursuant to the Debt
Documents or otherwise granted to or held by Agent, for the benefit of Agent and each Lender; and (iv) the agreements and obligations of Borrower contained in the Debt Documents and in this Agreement constitute the legal, valid and binding
obligations of Borrower, enforceable against Borrower in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of
creditors’ rights or by the application of general principles of equity; provided, however, with respect to this clause (iv), to the extent that this Agreement is not enforceable against Borrower, the obligations of Agent and the Lenders
contained herein with respect to such parties are null and void. 
 8. No Other Consents or Amendments. The consent in this
Agreement is applicable only to the matters set forth in Section 2 above, and do not constitute a future consent or waiver nor a consent to, or waiver of, anything other than the matters expressly set forth herein. Except as expressly
set forth in this Agreement, the Loan Agreement and all other Debt Documents shall remain unchanged and in full force and effect. This Agreement shall be limited precisely and expressly as drafted and shall not be

  
 5 

 
construed as consent to the amendment, restatement, modification, supplementation or waiver of any other terms or provisions of the Loan Agreement or any other Debt Document. 

9. Costs and Expenses. Borrower shall be responsible for the reimbursement of all fees and expenses of Agent’s in-house and
outside counsel and other out of pocket costs and expenses incurred by Agent and the Lenders in connection with the preparation and negotiation of this Agreement. Such fees, costs and expenses, as limited by the preceding sentence, shall be due and
payable upon demand of Agent, and if not paid promptly upon such demand, all such fees, costs and expenses shall become part of the Obligations. 

10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. 

11. Successors/Assigns. This Agreement shall bind, and the rights hereunder shall inure to, the respective successors and
assigns of the parties hereto, subject to the provisions of the Debt Documents. 
 12. Headings. Section headings in this
Agreement are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose. 
 13.
Counterparts. This Agreement may be executed in counterparts, and such counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of this Agreement by facsimile or other
electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by facsimile or other electronic method of transmission
also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability or binding effect of this Agreement. 

[SIGNATURE PAGE TO FOLLOW] 

  
 6 

 IN WITNESS WHEREOF, the undersigned have caused this Consent and Amendment Agreement to be
duly executed by their duly authorized representatives, all as of the day and year first above written. 
  

			
	BORROWER:
	
	Syndax Pharmaceuticals, Inc., a Delaware corporation
		
	By:	 	 /s/ Arlene M. Morris

	Name:	 	Arlene M. Morris
	Title:	 	Chief Executive Officer

 [Signatures Continue on Following Page] 

  
 S-1 

 
			
	AGENT AND LENDER:
	
	General Electric Capital Corporation, a Delaware corporation
		
	By:	 	 /s/ Jacqueline K. Blechinger

	Name:	 	Jacqueline K. Blechinger
	Its:	 	Duly Authorized Signatory

 [End of Signature Pages] 

  
 S-2 

 Exhibit A 

March 2013 Charter Amendments 

  
 Exhibit A 

 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 

OF 
 SYNDAX
PHARMACEUTICALS, INC. 
 Syndax Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware,
hereby certifies as follows: 
 The name of this corporation is Syndax Pharmaceuticals, Inc. This corporation was originally incorporated
under the same name, and the original Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on October 11, 2005. An Amended and Restated Certificate of Incorporation or Certificate of
Amendment to the Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on March 29, 2007, January 22, 2010, August 2, 2010, December 20,
2011, June 28, 2012, October 9, 2012, November 19, 2012, December 28, 2012, January 18, 2013 and March 8, 2013, all under its present name. 

The text of the Fifth Amended and Restated Certificate of Incorporation, as amended, is hereby amended and restated in its entirety to read as
follows: 
 ARTICLE I 

The name of this corporation is Syndax Pharmaceuticals, Inc. 

ARTICLE II 
 The address
of this corporation’s registered office in the State of Delaware is 2711 Centerville Road, Suite 400, City of Wilmington, 19808, County of New Castle, Delaware. The name of its registered agent at such address is Corporation Service Company.

 ARTICLE III 
 The
purpose of this corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware. 

ARTICLE IV 
 This
corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which this corporation is authorized to issue is two billion six hundred
fifty-two million (2,652,000,000) shares. Nine hundred thirty-four million (934,000,000) shares shall be Common Stock with a par value of $0.0001 per share and one billion seven hundred eighteen million (1,718,000,000) shares shall be
Preferred Stock with a par value of $0.001 per share, five hundred forty million (540,000,000) of which shall be designated Series A Preferred Stock (“Series A Preferred Stock”), four hundred eighty six million
(486,000,000) of which shall be designated Series A-1 Preferred Stock (“Series A-1 Preferred Stock”), three hundred fifty-five million (355,000,000) of which shall be designated Series B Preferred Stock (“Series B
Preferred Stock”) and three hundred thirty-seven million (337,000,000) of which shall be designated Series B-1 Preferred Stock (“Series B-1 Preferred  

 
Stock” and, collectively with the Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock, the “Preferred Stock”). This corporation shall
from time to time in accordance with the laws of the State of Delaware increase the authorized amount of its Common Stock if at any time the number of shares of Common Stock remaining unissued and available for issuance upon conversion of the
Preferred Stock shall not be sufficient to permit conversion of the Preferred Stock. Subject to the provisions herein, the number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then
outstanding) by the affirmative vote of the holders of shares of stock of this corporation representing a majority of the votes represented by all outstanding shares of stock of this corporation entitled to vote, irrespective of the provisions of
Section 242(b)(2) of the Delaware General Corporation Law. 
 ARTICLE V 

The relative rights, preferences, privileges and restrictions granted to or imposed upon the respective classes and series of the shares of
capital stock or the holders thereof are as follows: 
 1. Dividend Provisions. Prior and in preference to any declaration or
payment of any dividends to the holders of shares of Series A Preferred Stock, Series B Preferred Stock, Common Stock, or any other class of capital stock of this corporation, the holders of shares of the Series A-1 Preferred Stock and Series B-1
Preferred Stock (together, the “Prime Preferred Stock”) shall be entitled to receive cumulative dividends whether or not declared by the board of directors of this corporation, on a pari passu basis, out of any assets legally
available therefor (payable other than in Common Stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of Common Stock of this corporation), at the rate of six
percent (6%) of the applicable Original Issue Price (as defined herein) per share per annum. Such dividends shall accrue and be cumulative from the date of issuance of the shares of Prime Preferred Stock, whether or not earned or declared by
the board of directors of this corporation. In the event that the board of directors of this corporation declares a dividend, the amount of which is insufficient to permit payment of the full aforesaid dividends, such dividends will be paid ratably
to each holder in proportion to the dividend amounts to which each holder of Prime Preferred Stock is entitled. Any dividend payment made on shares of Prime Preferred Stock shall first be credited against the dividends accumulated with respect to
the earliest dividend period for which dividends have not been paid. In addition, holders of shares of Prime Preferred Stock shall be entitled to receive, on an as-converted basis, dividends declared and paid to holders of Common Stock. The
“Original Issue Price” of each series of the Preferred Stock shall be Nine and One-Tenth Cents ($0.091) per share (as adjusted for stock splits, stock dividends, recapitalization and similar events). 

2. Liquidation Preference. 

(a) Preferred Preference. 

(i) In the event of any Liquidating Transaction (as defined below), either voluntarily or involuntarily, the holders of each series of the
Prime Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus 

 
funds of this corporation (or distribution of consideration in connection with a Liquidating Transaction) to the holders of Series A Preferred Stock, Series B Preferred Stock and Common Stock, on
a pari passu basis, an amount equal to the applicable Original Issue Price per share for each share of Prime Preferred Stock then so held, plus a further amount equal to any accrued but unpaid dividends on such shares. All of the preferential
amounts to be paid to the holders of the Prime Preferred Stock under this Section 2(a)(i) shall be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the distribution of any assets of this
corporation to, the holders of the Series A Preferred Stock, Series B Preferred Stock or Common Stock in connection with such Liquidating Transaction. 

(ii) If, upon such Liquidating Transaction the assets of this corporation are insufficient to provide for the cash payment of the full
aforesaid preferential amounts to the holders of the Prime Preferred Stock, such assets as are available shall be distributed ratably among the holders of the Prime Preferred Stock in proportion to the full preferential amount each such holder is
otherwise entitled to receive. 
 (iii) After payment has been made to the holders of the Prime Preferred Stock of the full amounts to which
they are entitled as provided in Section 2(a)(i) above, the remaining assets of this corporation available for distribution to the stockholders shall be distributed pro rata among the holders of Series B Preferred Stock, prior and in
preference to any distribution of any of the assets or surplus funds of this corporation (or distribution of consideration in connection with a Liquidating Transaction) to the holders of Series A Preferred Stock and Common Stock, an amount equal to
seventy-five percent (75%) of the applicable Original Issue Price per share for each share of Series B Preferred Stock then so held, plus a further amount equal to any dividends declared but unpaid on such shares. All of the preferential
amounts to be paid to the holders of the Series B Preferred Stock under this Section 2(a)(iii) shall be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the distribution of any assets of
this corporation to, the holders of the Series A Preferred Stock and Common Stock in connection with such Liquidating Transaction. If, upon such Liquidating Transaction the assets of this corporation are insufficient to provide for the cash payment
of the full aforesaid preferential amounts to the holders of the Series B Preferred Stock, such assets as are available shall be distributed ratably among the holders of the Series B Preferred Stock in proportion to the full preferential amount each
such holder is otherwise entitled to receive. 
 (iv) After payment has been made to the holders of the Preferred Stock of the full amounts
to which they are entitled as provided in Sections 2(a)(i) and 2(a)(iii) above, the remaining assets of this corporation available for distribution to the stockholders shall be distributed pro rata among the holders of Common Stock,
Prime Preferred Stock and Series A Preferred Stock (on an as-converted to Common Stock basis, provided that for purposes of this Section 2(a)(iv), the “Series A Conversion Price” of each share of Series A Preferred Stock shall
be five times the Series A Conversion Price then in effect pursuant to Section 4 below). 
 (v) If any portion of the
consideration payable to the stockholders of this corporation is placed into escrow and/or is payable to the stockholders of this corporation subject to contingencies, the agreement governing such transaction shall provide that (x) the portion
of such consideration that is not placed in escrow and not subject to any contingencies 

 
(the “Initial Consideration”) shall be allocated among the holders of capital stock of this corporation in accordance with the liquidation preference order as set forth in this
Section 2 as if the Initial Consideration were the only consideration payable in connection with such Liquidating Transaction and (y) any additional consideration which becomes payable to the stockholders of this corporation upon
release from escrow or satisfaction of contingencies shall be allocated among the holders of capital stock of this corporation in accordance with the liquidation preference order as set forth in this Section 2 after taking into account
the previous payment of the Initial Consideration as part of the same transaction. 
 For purposes of this Section 2, a
“Liquidating Transaction” of this corporation shall mean a (i) liquidation, dissolution or winding-up of this corporation, (ii) sale, conveyance, license or other disposition of all or substantially all of the assets,
property or business of this corporation, or, (iii) merger or consolidation with or into any other corporation if, as a result of such merger or consolidation, the holders of the Common Stock and Preferred Stock prior to such merger or
consolidation do not hold at least fifty-one percent (51%) of the combined voting power of the surviving corporation. 
 (b)
Notice of Liquidating Transaction. This corporation shall give each holder of record of Preferred Stock written notice of any impending Liquidating Transaction not later than ten (10) days prior to the stockholders’ meeting called
to approve such Liquidating Transaction, or ten (10) days prior to the closing of such Liquidating Transaction, whichever is earlier, and shall also notify such holders in writing of the final approval of such Liquidating Transaction. The first
of such notices shall describe the material terms and conditions of the impending Liquidating Transaction and the provisions of this Section 2, and this corporation shall thereafter give such holders prompt notice of any material
changes. Unless such notice requirements are waived, the Liquidating Transaction shall not take place sooner than ten (10) days after this corporation has given the first notice provided for herein or sooner than ten (10) days after this
corporation has given notice of any material changes provided for herein. Notwithstanding the other provisions of this Sixth Amended and Restated Certificate of Incorporation, all notice periods or requirements in this Certificate of Incorporation
applicable to the holders of Preferred Stock may be shortened or waived, either before or after the action for which notice is required, upon the written consent of the holders of at least sixty percent (60%) of the voting power of the
outstanding shares of Preferred Stock that are entitled to such notice rights. 
 (c) Consent for Certain Repurchases. Each
holder of an outstanding share of Preferred Stock shall be deemed to have consented, for purposes of Section 160 of the General Corporation Law of the State of Delaware (and, if applicable, Sections 502, 503 and 506 of the California
Corporations Code), to distributions made by this corporation in connection with the repurchase of shares of Common Stock issued to or held by employees or consultants upon termination of their employment or services pursuant to agreements providing
for the right of said repurchase between this corporation and such persons but only to the extent each distribution equals the original purchase price of such shares being repurchased. 

3. Voting Rights. 
 (a)
The Preferred Stock, voting together as a separate class, shall be entitled to elect three (3) members of the board of directors (the “Preferred Directors”); the Common Stock, voting as a separate class, shall be entitled to
elect two (2) members of the board of directors (the 

 
“Common Directors”); and the holders of a majority of the Common Stock and a majority of the Preferred Stock, voting as a separate class on an as converted basis, shall be
entitled to elect one (1) member, and the holders of at least sixty percent (60%) of the Preferred Stock and a majority of the Common Stock, voting as a separate class, shall be entitled to elect any additional directors. 

(b) On all other matters, except as specifically provided herein or as otherwise required by law, holders of the Preferred Stock shall have
full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall be entitled to vote, together with the holders of Common Stock, with respect to any matters upon which holders of Common Stock have the
right to vote. Except as otherwise provided herein, the holder of each share of Common Stock issued and outstanding shall have one vote and the holder of each share of Preferred Stock shall be entitled to the number of votes equal to the largest
number of shares of Common Stock into which such share of Preferred Stock could be converted at the record date for determination of the stockholders entitled to vote on such matters, or, if no such record date is established, at the date such vote
is taken or any written consent of stockholders is solicited, such votes to be counted together with all other shares of stock of this corporation having general voting power and not separately as a class. For purposes of this Section 3,
the “voting power of the shares of Preferred Stock” shall mean the number of votes equal to the number of shares of Common Stock into which such shares of Preferred Stock could be converted at the dates provided in the preceding sentence.
Fractional votes by the holders of Preferred Stock shall not, however, be permitted and any fractional voting rights shall (after aggregating all shares into which shares of Preferred Stock held by each holder could be converted) be rounded to the
nearest whole number. 
 4. Conversion. The holders of the Preferred Stock shall have conversion rights as follows (the
“Conversion Rights”): 
 (a) Right to Convert. Each share of Preferred Stock shall be convertible into shares of
Common Stock without the payment of any additional consideration by the holder thereof and, at the option of the holder thereof, at any time after the date of issuance of such share, at the office of this corporation or any transfer agent for the
Preferred Stock and shall be convertible into the number of fully paid and nonassessable shares of Common Stock which results from dividing the per share Conversion Value (as hereinafter defined) of each series of Preferred Stock at the time of
conversion by the Conversion Price (as hereinafter defined) per share in effect for such series. The initial per share Conversion Price of the Series A Preferred Stock shall be Nine and One-Tenth Cents ($0.091). The per share Conversion Value of the
Series A Preferred Stock shall be Nine and One-Tenth Cents ($0.091) (as adjusted for stock splits, stock dividends, recapitalization and similar events relating to the Series A Preferred Stock). The initial per share Conversion Price of the Series
A-1 Preferred Stock shall be Nine and One-Tenth Cents ($0.091). The per share Conversion Value of the Series A-1 Preferred Stock shall be Nine and One-Tenth Cents ($0.091) (as adjusted for stock splits, stock dividends, recapitalization and similar
events relating to the Series A-1 Preferred Stock). The initial per share Conversion Price of the Series B Preferred Stock shall be Nine and One-Tenth Cents ($0.091). The per share Conversion Value of the Series B Preferred Stock shall be Nine and
One-Tenth Cents ($0.091) (as adjusted for stock splits, stock dividends, recapitalization and similar events relating to the Series B Preferred Stock). The initial per share Conversion Price of the Series B-1 Preferred Stock shall be Nine and
One-Tenth Cents ($0.091). The per share Conversion Value of the Series B-1 Preferred Stock shall be Nine and One-Tenth Cents 

 
($0.091) (as adjusted for stock splits, stock dividends, recapitalization and similar events relating to the Series B-1 Preferred Stock). The initial Conversion Price of each series of Preferred
Stock shall be subject to adjustment from time to time as provided below, subject to the terms of Section 4(e) hereof. The number of shares of Common Stock into which a share of Preferred Stock is convertible is hereinafter referred to
as the “Conversion Rate” of such series. 
 (b) Automatic Conversion. Each share of Preferred Stock shall
automatically be converted into share(s) of Common Stock at its then effective Conversion Rate of such series of Preferred Stock immediately upon the earlier of (i) the closing of the sale of this corporation’s Common Stock in a firm
commitment, underwritten public offering registered under the Securities Act of 1933, as amended (“Securities Act”), with aggregate offering proceeds to this corporation (before deduction for underwriters’ discounts and
expenses relating to the issuance) of at least Fifty Million Dollars ($50,000,000) and a public offering price per share equal to at least three (3) times the Original Issue Price for the Series B-1 Preferred Stock, or (ii) at the election
of the holders of at least sixty percent (60%) of the outstanding shares of the Preferred Stock voting as a separate class on an as-converted basis. 

(c) Mechanics of Conversion. Before any holder of Preferred Stock shall be entitled to convert the same into shares of Common
Stock, the holder shall surrender the certificate(s) therefor, duly endorsed, at the office of this corporation or of any transfer agent for the Preferred Stock and shall give written notice to this corporation at such office that the holder elects
to convert the same (except that no such written notice of election to convert shall be necessary in the event of an automatic conversion pursuant to Section 4(b) hereof). This corporation shall, as soon as practicable thereafter, issue
and deliver at such office to such holder of Preferred Stock certificate(s) for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed to have been made immediately prior to the
close of business on the date of such surrender of the shares of Preferred Stock to be converted (except that in the case of an automatic conversion pursuant to Section 4(b)(i) hereof such conversion shall be deemed to have been made
immediately prior to the closing of the offering referred to in Section 4(b)(i)) or in the case of an automatic conversion pursuant to Section 4(b)(ii) hereof, immediately prior to the close of business on the date of the
election referred to in Section 4(b)(ii) and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common
Stock on such date. If the conversion is in connection with an underwritten public offering of securities registered pursuant to the Securities Act, the conversion may, at the option of any holder tendering such Preferred Stock for conversion, be
conditioned upon the closing with the underwriters of the sale of securities pursuant to such offering, in which event any persons entitled to receive Common Stock upon conversion of such Preferred Stock shall not be deemed to have converted such
Preferred Stock until immediately prior to the closing of such sale of securities. 
 (d) Fractional Shares. In lieu of any
fractional shares to which the holder of Preferred Stock would otherwise be entitled, this corporation shall pay cash equal to such fraction multiplied by the fair market value of one share of such series of Preferred Stock as determined by the
board of directors of this corporation. Whether or not fractional shares are issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock of each holder at the time converting into Common Stock and
the number of shares of Common Stock issuable upon such aggregate conversion. 

 (e) Adjustment of Conversion Price. The Conversion Price of the Series A Preferred
Stock (“Series A Conversion Price”), the Conversion Price of the Series A-1 Preferred Stock (“Series A-1 Conversion Price”), the Conversion Price of the Series B Preferred Stock (“Series B Conversion
Price”) and the Conversion Price of the Series B-1 Preferred Stock (“Series B-1 Conversion Price” and, collectively with the Series A Conversion Price, Series A-1 Conversion Price and Series B Conversion Price, each a
“Preferred Stock Conversion Price”) shall each be subject to independent adjustment from time to time as follows: 
 (i)
Definitions. For purposes of this paragraph 4(e), the following definitions shall apply: 
 (A) “Excluded
Stock” shall mean: 
 (1) all shares of Common Stock issued or deemed issued to directors or employees of, or consultants or
advisors to, this corporation, pursuant to any stock option plan or equity incentive plan of this corporation approved by a majority of the board of directors of this corporation; 

(2) all shares of Common Stock issued or deemed issued in connection with research and development partnerships, licensing, corporate
partnering, collaborative arrangements or similar transactions approved by the holders of at least sixty percent (60%) of the outstanding Preferred Stock; 

(3) all securities issued pursuant to dividends or distributions on the Preferred Stock; 

(4) securities to financial institutions or lessors issued in connection with commercial credit arrangements, equipment financings, commercial
property lease transactions, or similar transactions approved by a majority of the board of directors of this corporation; 
 (5) capital
stock issued in connection with bona fide acquisitions, mergers, consolidations or similar business combinations, provided that such issuance has been approved by the holders of at least sixty percent (60%) of the outstanding Preferred Stock;

 (6) Common Stock issuable upon conversion of the Preferred Stock; 

(7) Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock issued upon conversion of
Preferred Stock or Debt (as defined below) pursuant to Section 5(a)(i) below; 
 (8) RESERVED; 

(9) Warrants to purchase Preferred Stock (the “Preferred Stock Warrants”) issued in connection with that certain Series B-1
Preferred Stock and Warrant Purchase Agreement dated as of the date of this Sixth Amended and Restated Certificate of Incorporation (“2013 Purchase Agreement”); 

(10) Preferred Stock issued upon exercise of the Preferred Stock Warrants; 

 (11) shares of Common Stock or Convertible Securities issued upon the exercise of Options or
shares of Common Stock issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; and 

(12) all securities issued pursuant to a firm commitment, underwritten initial public offering of the capital stock of this corporation
registered under the Securities Act. 
 (B) “Options” means rights, options or warrants to subscribe for, purchase
or otherwise acquire either Common Stock or Convertible Securities. 
 (C) “Convertible Securities” means securities
by their terms directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. 
 (D)
“Purchase Rights” means Options and Convertible Securities. 
 (E) “Dilutive Issuance” means an
issuance of Purchase Rights, or Common Stock which is not Excluded Stock, without consideration or for a consideration per share less than the applicable Preferred Stock Conversion Price. “Dilutive Issuance” excludes any stock
dividend, subdivision or split-up, stock combination, dividend or Transaction described in Sections 4(e)(iv) through (vii) below. 

(ii) Adjustment of Conversion Price for Dilutive Issuances. 

(A) If this corporation issues or is deemed to issue any Common Stock in a Dilutive Issuance at any time after the initial date shares of
Series B-1 Preferred Stock are issued and on or before December 31, 2013, then (1) the Series B-1 Conversion Price in effect after each such issuance shall be reduced to the consideration per share received by this corporation for such
issue or deemed issue of Common Stock in a Dilutive Issuance; provided that if such issuance or deemed issuance was without consideration, then this corporation shall be deemed to have received an aggregate of $0.001 of consideration
for all such Common Stock in a Dilutive Issuance issued or deemed to be issued and (2) the Series A-1 Conversion Price and the Series B Conversion Price in effect after each such issuance shall be adjusted to a price determined pursuant to
Section 4(e)(ii)(B) below as if the Dilutive Issuance occurred after December 31, 2013. 
 (B) If this corporation issues or is
deemed to issue any Common Stock in a Dilutive Issuance after December 31, 2013, the Series A-1 Conversion Price, Series B-1 Conversion Price and Series B Conversion Price in effect after each such issuance shall be adjusted to a price
determined by multiplying the Preferred Stock Conversion Price in effect immediately prior to the Dilutive Issuance by a fraction: 
 (1)
the numerator of which shall be (x) the number of shares of Common Stock outstanding and issuable on exercise of all outstanding Options and Convertible Securities immediately prior to the Dilutive Issuance, plus (y) the number of shares
of Common Stock that the aggregate consideration, if any, received by this corporation in connection with the Dilutive Issuance would purchase at such Preferred Stock Conversion Price, and 

(2) the denominator of which shall be (x) the number of shares of Common Stock outstanding and issuable on exercise of all outstanding
Options and 

 
Convertible Securities immediately prior to the Dilutive Issuance, plus (y) the number of shares of Common Stock issued or deemed issued in the Dilutive Issuance. 

(C) For the avoidance of doubt, the Series A Conversion Price shall not be automatically adjusted pursuant to this Section 4(e)(ii) in
connection with a Dilutive Issuance. 
 (iii) For purposes of any adjustment of the Preferred Stock Conversion Price pursuant to clause
(ii) above, the following provisions shall be applicable: 
 (A) In the case of the issuance of Common Stock for cash, the
consideration shall be deemed to be the amount of cash paid therefor after deducting any discounts or commissions paid or incurred by this corporation in connection with the issuance and sale thereof. 

(B) In the case of the issuance of Common Stock for a consideration in whole or in part other than cash, the consideration other than cash
shall be deemed to be the fair market value thereof as determined by the board of directors of this corporation, in accordance with generally accepted accounting treatment; provided, however, that if at the time of such determination, this
corporation’s Common Stock is traded in the over-the-counter market or on a national or regional securities exchange, such fair market value as determined by the board of directors of this corporation shall not exceed the aggregate
“Current Market Price” (as defined below) of the shares of Common Stock being issued. 
 (C) In the case of the issuance of
Purchase Rights in a Dilutive Issuance: 
 (1) the aggregate maximum number of shares of Common Stock deliverable upon exercise of Options
shall be deemed to have been issued at the time such Options were issued and for a consideration equal to the consideration (determined in the manner provided in (iii) (A) and (B) above), if any, received by this corporation upon the
issuance of such Options plus the minimum purchase price provided in such Options covered thereby; 
 (2) the aggregate maximum number of
shares of Common Stock deliverable upon conversion or exercise of or exchange for any Convertible Securities shall be deemed to have been issued at the time such Convertible Securities were issued and for a consideration equal to the consideration
received by this corporation for any such Convertible Securities (excluding any cash received on account of accrued interest or accrued dividends), plus the minimum additional consideration, if any; to be received by this corporation upon the
conversion or exchange of such Convertible Securities (determined in the manner provided in (iii) (A) and (B) above); 
 (3)
on any change in the number of shares of Common Stock deliverable upon exercise of any such Purchase Rights or on any change in the minimum purchase price of such Purchase Rights, the Preferred Stock Conversion Price shall forthwith be readjusted to
such Preferred Stock Conversion Price as would have been obtained had the adjustment made upon (x) the issuance of such Purchase Rights not exercised, converted or exchanged prior to such change, as the case may be, been made upon the basis of
such change or (y) the issuance of options or rights related to such securities not converted or exchanged prior to such change, as the case may be, been made upon the basis of such change; and 

 (4) on the expiration of any Purchase Rights, the Preferred Stock Conversion Price shall
forthwith be readjusted to such Preferred Stock Conversion Price as would have obtained had the adjustment made upon the issuance of such Purchase Right been made upon the basis of the issuance of only the number of shares of Common Stock actually
issued upon the exercise of such Purchase Rights. 
 (iv) If the number of shares of Common Stock outstanding at any time after the date of
this Sixth Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware (the “Filing Date”) is increased by a stock dividend payable in shares of Common Stock or by a subdivision or
split-up of shares of Common Stock, then, on the date such payment is made or such change is effective, the applicable Conversion Price shall be appropriately decreased so that the number of shares of Common Stock issuable on conversion of any
shares of such Preferred Stock shall be increased in proportion to such increase of outstanding shares. 
 (v) If the number of shares of
Common Stock outstanding at any time after the Filing Date is decreased by a combination of the outstanding shares of Common Stock then, on the effective date of such combination, the applicable Conversion Price shall be appropriately increased so
that the number of shares of Common Stock issuable on conversion of any shares of Preferred Stock shall be decreased in proportion to such decrease in outstanding shares. 

(vi) In case this corporation shall declare a cash dividend upon its Common Stock payable otherwise than out of retained earnings or shall
distribute to holders of its Common Stock shares of its capital stock (other than Common Stock); stock or other securities of other persons, evidences of indebtedness issued by this corporation or other persons, assets (excluding cash dividends) or
options or rights (excluding Purchase Rights), then, in each such case, the holders of shares of Preferred Stock shall, concurrent with the distribution to holders of Common Stock, receive a like distribution based upon the number of shares of
Common Stock into which each series of Preferred Stock is convertible. 
 (vii) In case, at any time after the date hereof, of any capital
reorganization, or any reclassification of the stock of this corporation (other than as a result of a stock dividend or subdivision, split-up or combination of shares provided for under Section 4(e)(iv) or (v) above), or the
consolidation or merger of this corporation with or into another person (other than a consolidation or merger in which this corporation is the continuing entity and which does not result in any change in the Common Stock), or of the sale or other
disposition of all or substantially all the properties and assets of this corporation (“Transaction”), the shares of Preferred Stock shall, after such Transaction, be convertible into the kind and number of shares of stock or other
securities or property of this corporation or otherwise to which such holder would have been entitled if immediately prior to such Transaction the holder had converted the holder’s shares of Preferred Stock into Common Stock. The provisions of
this clause (vii) shall similarly apply to successive Transactions. 
 (viii) All calculations under this Section 4 shall
be made to the nearest cent or to the nearest 1/100 of a share, as the case may be. 
 (ix) For the purpose of any computation pursuant to
this Section 4(e), the “Current Market Price” at any date of one share of Common Stock, shall be deemed to be the average of the highest reported bid and the lowest reported offer prices on the preceding

 
business day as reported by Nasdaq (or equivalent recognized source of quotations); provided, however, that if the Common Stock is not traded in such manner that the quotations referred to in
this clause (ix) are available for the period required hereunder, Current Market Price shall be determined in good faith by the board of directors of this corporation. 

(f) Minimal Adjustments. No adjustment in the Conversion Price need be made if such adjustment would result in a change in the
Conversion Price of less than $0.01. Any adjustment of less than $0.01 which is not made shall be carried forward and shall be made at the time of and together with any subsequent adjustment which, on a cumulative basis, amounts to an adjustment of
$0.01 or more in the Conversion Price. 
 (g) [Reserved.] 

(h) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Rate pursuant to
this Section 4, this corporation at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to each holder of Preferred Stock a certificate setting forth such
adjustment or readjustment and showing in detail the facts upon which adjustment or readjustment is based. This corporation shall, upon request at any time of any holder of Preferred Stock, furnish or cause to be furnished to such holder a like
certificate setting forth (i) such adjustments and readjustments, (ii) the Conversion Rate at the time in effect, and (iii) the number of shares of Common Stock and the amount, if any, of other property which at the time would be
received upon the conversions of such holder’s shares of Preferred Stock. 
 (i) Notices of Record Date. In the event of
any taking by this corporation of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend) or other distribution, any right to
subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property or to receive any other right, this corporation shall mail to each holder of Preferred Stock at least twenty (20) days prior to
such record date, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution or right, and the amount and character of such dividend, distribution or right. 

(j) Reservation of Stock Issuable Upon Conversion. This corporation shall at all times reserve and keep available out of its
authorized but unissued shares of Common Stock solely for the purpose of effecting the conversion of the shares of Preferred Stock such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all
outstanding shares of Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of Preferred Stock, this corporation will take
such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose. 

(k) Notices. Any notice required by the provisions of this Section 4 to be given to the holder of shares of
Preferred Stock shall be deemed given if deposited in the United States mail, postage prepaid, and addressed to each holder of record at such holder’s address appearing on the books of this corporation. 

5. Special Mandatory Conversions. 

 (a) Trigger Event. 

(i) Equity Securities. 

(A) In the event that any holder of shares of Preferred Stock participates in the First Equity Closing (as defined in the 2013 Purchase
Agreement) of a Qualified Financing by purchasing at least such holder’s Pro Rata Amount (for the avoidance of doubt, the shares of Series B-1 Preferred Stock issued upon conversion and cancellation of the March 1, 2013 Notes (as
hereinafter defined) shall be deemed to be purchased at the initial closing of a Qualified Financing for purposes of determining whether such holder has purchased its Pro Rata Amount under this Section 5(a)(i) in the First Equity
Closing) at such closing , then, automatically, and without any further action on the part of such holder, and effective upon, subject to, and concurrently with, the consummation of such First Equity Closing, (1) each share of Series A
Preferred Stock held by such holder shall be converted into one share of Series A-1 Preferred Stock, and (2) the outstanding principal balance and all unpaid accrued interest, net of any required withholding taxes, of all Debt held by such
holder shall convert in whole into shares of Series B-1 Preferred Stock at a conversion price equal to the price per share paid by the participants in the Qualified Financing on the same terms and conditions as given to the participants in the
Qualified Financing. 
 (B) In the event that any holder of shares of Preferred Stock does not participate in any of the First Equity
Closing, Second Equity Closing (as defined in the 2013 Purchase Agreement) or Fourth Equity Closing (as defined in the 2013 Purchase Agreement) of the Qualified Financing by purchasing such holder’s Pro Rata Amount at such closing, then,
automatically, and without any further action on the part of such holder, and effective upon, subject to, and concurrently with, the consummation of such closing, (1) each share of Series A-1 Preferred Stock held by such holder immediately
prior thereto shall be converted into one share of Series A Preferred Stock, (2) each share of Series B-1 Preferred Stock issued to such holder pursuant to Section 5(a)(i)(A), shall be converted into one share of Series B Preferred
Stock, and (3) the outstanding principal balance and all unpaid accrued interest, net of any required withholding taxes, of all Debt, if any, held by such holder shall convert in whole into shares of Series B Preferred Stock at a conversion
price equal to the price per share paid by the participants in the Qualified Financing on the same terms and conditions as given to the participants in the Qualified Financing. Notwithstanding the foregoing, Section 5(a)(i)(A) and
(B) shall not apply to GE Capital Investments, Inc. or its Affiliates with respect to those shares of Series B-1 Preferred Stock issued to it or them pursuant to that certain Exchange Agreement by and between GE Capital Investments, Inc.
and this corporation on or about the date of this Sixth Amended and Restated Certificate of Incorporation. This Sixth Amended and Restated Certificate of Incorporation shall not, without the written consent of GE Capital Investments, Inc., be
amended such that the immediately foregoing sentence is modified. 
 (C) The conversions and issuances of equity securities contemplated by
this Section 5(a)(i) are referred to as “Special Mandatory Conversions.” No fractional shares shall be issued upon a Special Mandatory Conversion. In lieu of any fractional shares, this corporation shall pay to the
holder an amount in cash equal to the product obtained by multiplying the applicable conversion price set forth in the applicable Debt by the fraction of a share not issued upon such conversion. 

 (ii) Affiliate Aggregation. For purposes of determining (A) the number of shares of
Preferred Stock and Preferred Stock into which Debt is convertible by a holder thereof, (B) such holder’s Pro Rata Amount and (C) the number of Offered Securities such holder has purchased in a Qualified Financing, all shares of
Preferred Stock and shares of Preferred Stock into which Debt is convertible held by Affiliates of such holder shall be aggregated with such holder’s shares and all Offered Securities purchased by Affiliates of such holder shall be aggregated
with the Offered Securities purchased by such holder (provided that no shares or securities shall be attributed to more than one entity or person within any such group of affiliated entities or persons). 

(b) Procedural Requirements. 

(i) Upon a Special Mandatory Conversion, each holder of shares or Debt converted pursuant to Section 5(a) shall be sent written notice of
such Special Mandatory Conversion. Upon receipt of such notice, each holder of such securities shall surrender his, her or its certificate(s) for all such shares of applicable Preferred Stock and Debt (“Securities Documentation”)
(or, if such holder alleges that such Securities Documentation has been lost, stolen or destroyed, an affidavit certifying to its loss and agreement reasonably acceptable to this corporation to indemnify this corporation against any claim that may
be made against this corporation on account of the alleged loss, theft or destruction of such Securities Documentation) to this corporation at the place designated in such notice. If so required by this corporation, Securities Documentation
surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to this corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing.
All rights with respect to the securities converted pursuant to Section 5(a), including the rights, if any, to receive notices and vote, will terminate at the time of the Special Mandatory Conversion (notwithstanding the failure of the holder
or holders thereof to surrender the Securities Documentation for such shares or Debt at or prior to such time), except only the rights of the holders thereof, upon surrender of their certificate or certificates therefor (or lost certificate
affidavit and agreement), to receive the items provided for in Section 5(b)(ii). 
 (ii) As soon as practicable after the Special
Mandatory Conversion and the surrender of the certificate(s) (or lost certificate affidavit and agreement) for applicable Preferred Stock and Debt so converted, this corporation shall issue and deliver to such holder, or to his, her or its nominees,
a certificate or certificates for the number of full shares of Preferred Stock issuable on such conversion in accordance with the provisions hereof, together with cash as provided in Section 5(a)(i)(C) in lieu of any fraction of a share
of Preferred Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as
shares of such series, and this corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. 

(c) Definitions. For purposes of this Section 5, the following definitions shall apply: 

(i) “Affiliate” means, with respect to any holder of shares of Preferred Stock or Debt, any person, entity or firm
which, directly or indirectly, controls, is controlled by or is under common control with such holder, including, without limitation, any entity of which 

 
the holder is a partner or member, any partner, officer, director, member or employee of such holder and any fund now or hereafter existing of which the holder is a partner or member which is
controlled by or under common control with one or more general partners of such holder or shares the same management company with such holder. 

(ii) “Debt” means convertible promissory notes issued by this corporation other than those certain promissory notes
issued by this corporation on March 1, 2013 (A) to DP VIII Associates, L.P. in the principal amount of $165.72; (B) to Domain Partners VIII, L.P. in the principal amount of $22,334.28; (C) to MPM BioVentures IV-QP, L.P. in the
principal amount of $18,744.82; (D) to MPM BioVentures IV GmbH & Co. Beteiligungs KG in the principal amount of $722.16; (E) to MPM Asset Management Investors BV4 LLC in the principal amount of $533.02; and (F) to MPM
BioVentures IV Strategic Fund, L.P. in the principal amount of $2,500.00 (such excepted promissory notes are collectively referred to herein as the “March 1, 2013 Notes”). 

(iii) “Offered Securities” means the Series B-1 Preferred Stock set aside by the board of directors of this
corporation for purchase by holders of outstanding shares of Preferred Stock in connection with a Qualified Financing, and offered to such holders. 

(iv) “Pro Rata Amount” means the lesser of (a) a number of Offered Securities calculated by multiplying the
aggregate number of Offered Securities in any closing of the Qualified Financing by a fraction, the numerator of which is equal to the aggregate number of shares of Series A Preferred Stock held by such holder (giving effect to the conversion of
such holder’s Debt convertible into Preferred Stock as if converted into shares of Series A Preferred Stock) immediately prior to the First Equity Closing of a Qualified Financing, and the denominator of which is equal to the sum of the
aggregate number of shares of Series A Preferred Stock outstanding (giving effect to the conversion of all Debt as if converted into shares of Series A Preferred Stock) immediately prior to the First Equity Closing of the Qualified Financing, and
(b) the maximum number of Offered Securities that such holder is permitted by this corporation to purchase in such closing of the Qualified Financing, after giving effect to any cutbacks or limitations established by the board of directors and
applied on a pro rata basis to all stockholders of this corporation that were holders of Series A Preferred Stock immediately prior to the First Equity Closing. 

(v) “Qualified Financing” means each of the First Equity Closing, the Second Equity Closing and the Fourth Equity Closing of
the Series B-1 Preferred Stock and warrant financing contemplated by the 2013 Purchase Agreement. 
 6. Prime Preferred Stock Protective
Provisions. So long as at least One Million (1,000,000) shares of Prime Preferred Stock are outstanding, this corporation shall not (by merger, reclassification or otherwise), without first obtaining the approval (by vote or written consent, as
provided by law) of the holders of at least sixty percent (60%) of the then outstanding shares of Prime Preferred Stock voting as a single class: 

(a) amend the Certificate of Incorporation or Bylaws to alter or change the rights, preferences or privileges of the Preferred Stock; 

(b) increase or decrease the aggregate number of authorized shares of any class of stock; 

 (c) increase the number of shares reserved under any stock option plan of this corporation; 

(d) create or effect a creation (by reclassification or otherwise) of any new class or series of shares of stock; 

(e) effect any (i) Liquidating Transaction or (ii) an agreement for the sale of capital stock such that the stockholders immediately
prior to such sale will possess less than fifty percent (50%) of the voting power immediately after such sale; 
 (f) declare or pay
dividends on any capital stock (except as provided for in this Sixth Amended and Restated Certificate of Incorporation); 
 (g) execute any
action to increase or decrease the number of directors of this corporation; 
 (h) repurchase or redeem any shares of capital stock except in
connection with the repurchase of shares of Common Stock issued to or held by employees or consultants upon termination of their employment or services pursuant to agreements providing for the right of said repurchase between this corporation and
such persons but only to the extent each repurchase equals the original purchase price of such shares being repurchased; or 
 (i) do any act
or thing which would result in taxation of the holders of shares of the Preferred Stock under Section 305 of the Internal Revenue Code of 1986, as amended (or any comparable provision of the Internal Revenue Code as hereafter from time to time
amended). 
 ARTICLE VI 

This corporation is to have perpetual existence. 

ARTICLE VII 
 1.
Limitation of Liability. To the fullest extent permitted by the General Corporation Law of the State of Delaware as the same exists or as may hereafter be amended, a director of this corporation shall not be personally liable to this
corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. 
 2. Indemnification. This
corporation may indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that such person or his or
her testator or intestate is or was a director, officer or employee of this corporation, or any predecessor of this corporation; or serves or served at any other enterprise as a director, officer or employee at the request of this corporation or any
predecessor to this corporation. 
 3. Amendments. Neither any amendment nor repeal of this Article VII, nor the
adoption of any provision of this corporation’s Sixth Amended and Restated Certificate of Incorporation inconsistent with this Article VII, shall eliminate or reduce the effect of this Article VII, in respect of any matter
occurring, or any action or proceeding accruing or arising or 

 
that, but for this Article VII would accrue or arise, prior to such amendment repeal, or adoption of an inconsistent provision. 

ARTICLE VIII 
 In the
event that shares of Preferred Stock shall be converted pursuant to the terms hereof, the shares so converted shall not revert to the status of authorized but unissued shares, but instead shall be canceled and shall not be re-issuable by this
corporation. 
 ARTICLE IX 

Holders of stock of any class or series of this corporation shall not be entitled to cumulate their votes for the election of directors or any
other matter submitted to a vote of the stockholders. 
 ARTICLE X 

Elections of directors need not be by written ballot unless the Bylaws of this corporation so provide. 

ARTICLE XI 
 This
corporation hereby renounces, to the fullest extent permitted by Section 122 (17) of the General Corporation Law of the State of Delaware, any interest or expectancy of this corporation in, or in being offered, an opportunity to
participate in, any Preferred Stock Business Opportunity. A “Preferred Stock Business Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the
possession of, (i) any director of this corporation who is not an employee of this corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such
holder, other than someone who is an employee of this corporation or any of its subsidiaries (collectively, “Covered Persons”), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or
otherwise comes into the possession of, a Covered Person solely in such Covered Person’s capacity as a director of this corporation. To the fullest extent permitted by law, this corporation hereby waives any claim against a Covered Person, and
agrees to indemnify all Covered Persons against any claim, that is based on fiduciary duties, the corporate opportunity doctrine or any other legal theory which could limit any Covered Person from pursuing or engaging in any Preferred Stock Business
Opportunity. 
 ARTICLE XII 

In furtherance and not in limitation of the powers conferred by statute, the board of directors of this corporation is expressly authorized to
make, alter, amend or repeal the Bylaws of this corporation. 
 ARTICLE XIII 

The foregoing amendment and restatement of the Certificate of Incorporation has been duly approved by the board of directors of this
corporation. 

 The foregoing Sixth Amended and Restated Certificate of Incorporation has been duly adopted by this
corporation’s Board of Directors and stockholders in accordance with applicable provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware. I further declare under penalty of perjury under the laws of the
State of Delaware that the matters set forth in this certificate are true, correct and of my own knowledge. 
 Dated: March 8, 2013 

 

	
	/s/ Arlene M. Morris
	Arlene M. Morris
	Chief Executive Officer

 FOURTH CERTIFICATE OF AMENDMENT 

TO 
 FIFTH AMENDED AND
RESTATED 
 CERTIFICATE OF INCORPORATION 

OF 
 SYNDAX
PHARMACEUTICALS, INC. 
 SYNDAX PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 
 FIRST: That resolutions setting
forth a proposed fourth amendment to the Fifth Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and directing that said amendment be considered by the stockholders of the Corporation,
were duly adopted by the Board of Directors of the Corporation, acting by unanimous written consent. 
 SECOND: That said amendment was
approved by the stockholders of the Corporation entitled to vote on such amendment acting by written consent in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware. 

THIRD: That said amendment amends the Fifth Amended and Restated Certificate of Incorporation (the “Certificate of
Incorporation”) of the Corporation as follows: 
 A. By deleting the existing Article IV therein in its entirety and
substituting therefor a new Article IV to read in its entirety as follows: 
 ARTICLE IV 

This corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and
“Preferred Stock.” The total number of shares which this corporation is authorized to issue is two billion eight hundred sixteen (2,816,000,000) shares. One billion two hundred ten million five hundred thousand
(1,210,500,000) shares shall be Common Stock with a par value of $0.0001 per share and one billion six hundred five million five hundred thousand (1,605,500,000) shares shall be Preferred Stock with a par value of $0.001 per share, seven
hundred eighty million (780,000,000) of which shall be designated Series A Preferred Stock (“Series A Preferred Stock”), seven hundred eighty million (780,000,000) of which shall be designated Series A-1 Preferred Stock
(“Series A-1 Preferred Stock” and together with the Series A Preferred Stock, the “Series A/A-1 Preferred Stock”) and forty-five million five hundred thousand (45,500,000) of which shall be designated Series B
Preferred Stock (“Series B Preferred Stock” and together with the Series A/A-1 Preferred Stock, the “Preferred Stock”). This corporation shall from time to time in 

 
accordance with the laws of the State of Delaware increase the authorized amount of its Common Stock if at any time the number of shares of Common Stock remaining unissued and available for
issuance upon conversion of the Preferred Stock shall not be sufficient to permit conversion of the Preferred Stock. Subject to the provisions herein, the number of authorized shares of Common Stock may be increased or decreased (but not below the
number of shares thereof then outstanding) by the affirmative vote of the holders of shares of stock of this corporation representing a majority of the votes represented by all outstanding shares of stock of this corporation entitled to vote,
irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. 
 Upon the filing and
effectiveness (the “Effective Time”) pursuant to the Delaware General Corporation Law of this Certificate of Amendment to the Certificate of Incorporation of this corporation, each one (1) share of Series A Preferred Stock
issued and outstanding immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be divided into ten (10) shares Series A Preferred Stock (the “Stock
Split”). Each certificate that immediately prior to the Effective Time represented shares of Series A Preferred Stock (“Old Certificates”), shall thereafter represent that number of shares of Series A Preferred Stock into
which the shares of Series A Preferred Stock represents by the Old Certificate shall have been divided. The “Conversion Price” and “Conversion Value” of the Series A Preferred Stock shall, immediately after the Effective Time, be
reduced to one-tenth (1/10th) of its value prior thereto. Following the Stock Split, the par value of the Series A Preferred Stock remains $0.001 per share. 

FOURTH: That said amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation
Law of the State of Delaware. 
 IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by Arlene M.
Morris, its Chief Executive Officer, this 8th day of March, 2013. 
  

			
	SYNDAX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Arlene M. Morris
	Name:	 	Arlene M. Morris
	Title:	 	Chief Executive Officer

 THIRD CERTIFICATE OF AMENDMENT 

TO 
 FIFTH AMENDED AND
RESTATED 
 CERTIFICATE OF INCORPORATION 

OF 
 SYNDAX
PHARMACEUTICALS, INC. 
 SYNDAX PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 
 FIRST: That resolutions setting forth
a proposed third amendment to the Fifth Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and directing that said amendment be considered by the stockholders of the Corporation, were duly
adopted by the Board of Directors of the Corporation, acting by unanimous written consent. 
 SECOND: That said amendment was approved by the
stockholders of the Corporation entitled to vote on such amendment acting by written consent in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware. 

THIRD: That said amendment amends the Fifth Amended and Restated Certificate of Incorporation of the Corporation by deleting the existing
Article IV of said Certificate of Incorporation in its entirety and substituting therefor a new Article IV to read in its entirety as follows: 

ARTICLE IV 
 This
corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which this corporation is authorized to issue is Two Hundred
Eighty-One Million Six Hundred Thousand (281,600,000) shares. One Hundred Twenty-One Million Fifty Thousand (121,050,000) shares shall be Common Stock with a par value of $0.0001 per share and One Hundred Sixty Million Five Hundred Fifty
Thousand (160,550,000) shares shall be Preferred Stock with a par value of $0.001 per share, Seventy-Eight Million (78,000,000) of which shall be designated Series A Preferred Stock (“Series A Preferred Stock”),
Seventy-Eight Million (78,000,000) of which shall be designated Series A-1 Preferred Stock (“Series A-1 Preferred Stock” and together with the Series A Preferred Stock, the “Series A/A-1 Preferred Stock”) and
Four Million Five Hundred Fifty Thousand (4,550,000) of which shall be designated Series B Preferred Stock (“Series B Preferred Stock” and together with the Series A/A-1 Preferred Stock, the “Preferred Stock”).
This corporation shall from time to time in accordance with the laws of the State of Delaware increase the authorized amount of its Common Stock if at any time the number of shares of Common Stock remaining unissued and available for issuance upon
conversion of the Preferred Stock shall not be sufficient to permit conversion of the Preferred Stock. Subject to the provisions herein, the number of authorized shares of Common Stock may be increased or decreased (but not below the number of
shares thereof then outstanding) by the affirmative vote of the holders of shares of stock of this corporation representing a majority of the votes 

 
represented by all outstanding shares of stock of this corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. 

FOURTH: That said amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation
Law of the State of Delaware. 
 IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by Arlene M.
Morris, its Chief Executive Officer, this 18th day of January, 2013. 
  

			
	SYNDAX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Arlene M. Morris
	Name:	 	Arlene M. Morris
	Title:	 	Chief Executive Officer

 SECOND CERTIFICATE OF AMENDMENT 

TO 
 FIFTH AMENDED AND
RESTATED 
 CERTIFICATE OF INCORPORATION 

OF 
 SYNDAX
PHARMACEUTICALS, INC. 
 SYNDAX PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 
 FIRST: That resolutions setting
forth a proposed second amendment to the Fifth Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and directing that said amendment be considered by the stockholders of the Corporation,
were duly adopted by the Board of Directors of the Corporation, acting by unanimous written consent. 
 SECOND: That said amendment was
approved by the stockholders of the Corporation entitled to vote on such amendment acting by written consent in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware. 

THIRD: That said amendment amends the Fifth Amended and Restated Certificate of Incorporation of the Corporation by deleting the existing
Article IV of said Certificate of Incorporation in its entirety and substituting therefor a new Article IV to read in its entirety as follows: 

ARTICLE IV 
 This
corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which this corporation is authorized to issue is Two Hundred
Seventy-Nine Million Five Hundred Thousand (279,500,000) shares. One Hundred Twenty Million (120,000,000) shares shall be Common Stock with a par value of $0.0001 per share and One Hundred Fifty-Nine Million Five Hundred Thousand
(159,500,000) shares shall be Preferred Stock with a par value of $0.001 per share, Seventy-Eight Million (78,000,000) of which shall be designated Series A Preferred Stock (“Series A Preferred Stock”), Seventy-Eight
Million (78,000,000) of which shall be designated Series A-1 Preferred Stock (“Series A-1 Preferred Stock” and together with the Series A Preferred Stock, the “Series A/A-1 Preferred Stock”) and Three Million
Five Hundred Thousand (3,500,000) of which shall be designated Series B Preferred Stock (“Series B Preferred Stock” and together with the Series A/A-1 Preferred Stock, the “Preferred Stock”). This corporation
shall from time to time in accordance with the laws of the State of Delaware increase the authorized amount of its Common Stock if at any time the number of shares of Common Stock remaining unissued and available for issuance upon conversion of the
Preferred Stock shall not be sufficient to permit conversion of the Preferred Stock. Subject to the provisions herein, the number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then
outstanding) by the affirmative vote of the holders of shares of stock of this corporation representing a majority of the votes represented by all outstanding shares of stock of this 

  
 2 

 
corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. 

FOURTH: That said amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation
Law of the State of Delaware. 
 IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by Arlene M.
Morris, its Chief Executive Officer, this 28th day of December, 2012. 
  

			
	SYNDAX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Arlene M. Morris
	Name:	 	Arlene M. Morris
	Title:	 	Chief Executive Officer

 CERTIFICATE OF AMENDMENT 

TO 
 FIFTH AMENDED AND
RESTATED 
 CERTIFICATE OF INCORPORATION 

OF 
 SYNDAX
PHARMACEUTICALS, INC. 
 SYNDAX PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 
 FIRST: That resolutions setting
forth a proposed amendment to the Fifth Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and directing that said amendment be considered by the stockholders of the Corporation, were duly
adopted by the Board of Directors of the Corporation, acting by unanimous written consent. 
 SECOND: That said amendment was approved by the
stockholders of the Corporation entitled to vote on such amendment acting by written consent in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware. 

THIRD: That said amendment amends the Fifth Amended and Restated Certificate of Incorporation of the Corporation by deleting the existing
Article IV of said Certificate of Incorporation in its entirety and substituting therefor a new Article IV to read in its entirety as follows: 

ARTICLE IV 
 This
corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which this corporation is authorized to issue is Two Hundred
Seventy-Five Million Three Hundred Thousand (275,300,000) shares. One Hundred Sixteen Million Six Hundred Fifty Thousand (116,650,000) shares shall be Common Stock with a par value of $0.0001 per share and One Hundred Fifty-Eight Million
Six Hundred Fifty Thousand (158,650,000) shares shall be Preferred Stock with a par value of $0.001 per share, Seventy-Eight Million (78,000,000) of which shall be designated Series A Preferred Stock (“Series A Preferred
Stock”), Seventy-Eight Million (78,000,000) of which shall be designated Series A-1 Preferred Stock (“Series A-1 Preferred Stock” and together with the Series A Preferred Stock, the “Series A/A-1 Preferred
Stock”) and Two Million Six Hundred Fifty Thousand (2,650,000) of which shall be designated Series B Preferred Stock (“Series B Preferred Stock” and together with the Series A/A-1 Preferred Stock, the
“Preferred Stock”). This corporation shall from time to time in accordance with the laws of the State of Delaware increase the authorized amount of its Common Stock if at any time the number of shares of Common Stock remaining
unissued and available for issuance upon conversion of the Preferred Stock shall not be sufficient to permit conversion of the Preferred Stock. Subject to the provisions herein, the number of authorized shares of Common Stock may be increased or
decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of shares of stock of this corporation representing a majority of the votes represented 

 
by all outstanding shares of stock of this corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. 

FOURTH: That said amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation
Law of the State of Delaware. 
 IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by Arlene M.
Morris, its Chief Executive Officer, this 19th day of November, 2012. 
  

			
	SYNDAX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Arlene M. Morris
	Name:	 	Arlene M. Morris
	Title:	 	Chief Executive Officer

 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 

OF 
 SYNDAX
PHARMACEUTICALS, INC. 
 Syndax Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware,
hereby certifies as follows: 
 The name of this corporation is Syndax Pharmaceuticals, Inc. This corporation was originally incorporated
under the same name, and the original Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on October 11, 2005. An Amended and Restated Certificate of Incorporation of this Corporation
was filed with the Secretary of State of the State of Delaware on March 29, 2007, January 22, 2010, August 2, 2010 and December 20, 2011 all under its present name. A Certificate of Amendment to the Certificate of
Incorporation of this Corporation was filed with the Secretary of State of the State of Delaware on June 28, 2012. 
 The text of the
Fourth Amended and Restated Certificate of Incorporation, as amended, is hereby amended and restated in its entirety to read as follows: 

ARTICLE I 
 The name of
this corporation is Syndax Pharmaceuticals, Inc. 
 ARTICLE II 

The address of this corporation’s registered office in the State of Delaware is 2711 Centerville Road, Suite 400, City of Wilmington,
19808, County of New Castle, Delaware. The name of its registered agent at such address is Corporation Service Company. 
 ARTICLE III

 The purpose of this corporation is to engage in any lawful act or activity for which a corporation may be organized under the General
Corporation Law of the State of Delaware. 
 ARTICLE IV 

This corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and
“Preferred Stock.” The total number of shares which this corporation is authorized to issue is Two Hundred Seventy-Two Million Three Hundred Thousand (272,300,000) shares. One Hundred Fifteen Million One Hundred Fifty Thousand
(115,150,000) shares shall be Common Stock with a par value of $0.0001 per share and One Hundred Fifty-Seven Million One Hundred Fifty Thousand (157,150,000) shares shall be Preferred Stock with a par value of $0.001 per share,
Seventy-Eight Million (78,000,000) of which shall be designated Series A Preferred Stock (“Series A Preferred Stock”), Seventy-Eight Million (78,000,000) of which shall be designated Series A-1 Preferred Stock
(“Series A-1 Preferred Stock” and together with the Series A Preferred Stock, the “Series A/A-1 Preferred Stock”) and One Million One Hundred Fifty Thousand (1,150,000) of which shall be designated Series B
Preferred Stock (“Series B Preferred Stock” and 

 
together with the Series A/A-1 Preferred Stock, the “Preferred Stock”). This corporation shall from time to time in accordance with the laws of the State of Delaware increase the
authorized amount of its Common Stock if at any time the number of shares of Common Stock remaining unissued and available for issuance upon conversion of the Preferred Stock shall not be sufficient to permit conversion of the Preferred Stock.
Subject to the provisions herein, the number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of shares of stock of this
corporation representing a majority of the votes represented by all outstanding shares of stock of this corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. 

ARTICLE V 
 The relative
rights, preferences, privileges and restrictions granted to or imposed upon the respective classes and series of the shares of capital stock or the holders thereof are as follows: 

1. Dividend Provisions. Prior and in preference to any declaration or payment of any dividends to the holders of shares of Common
Stock, the holders of shares of the Series A Preferred Stock and Series A-1 Preferred Stock shall be entitled to receive dividends, on a pari passu basis, out of any assets legally available therefor (payable other than in Common Stock or
other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of Common Stock of this corporation), at the rate of eight percent (8%) of the applicable Original Issue Price
(as defined herein) per share per annum. Such dividends shall be payable when, as and if declared by the board of directors of this corporation, and shall not be cumulative. In the event that the board of directors of this corporation declares a
dividend, the amount of which is insufficient to permit payment of the full aforesaid dividends, such dividends will be paid ratably to each holder in proportion to the dividend amounts to which each holder of Preferred Stock is entitled. After
payment of the full amount of the aforesaid dividends, any additional dividends declared shall be distributed to the holders of Common Stock. In addition, holders of shares of Series A Preferred Stock and Series A-1 Preferred Stock shall be entitled
to receive, on an as-converted basis, dividends declared and paid to holders of Common Stock. The “Original Issue Price” of each series of the Preferred Stock shall be Ninety-One Cents ($0.91) per share (as adjusted for stock
splits, stock dividends, recapitalization and similar events). 
 2. Liquidation Preference. 

(a) Preferred Preference. 

(i) In the event of any Liquidating Transaction (as defined below), either voluntarily or involuntarily, the holders of each series of the
Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of this corporation (or distribution of consideration in connection with a Liquidating Transaction (defined below)) to
the holders of Common Stock, on a pari passu basis, an amount equal to the applicable Original Issue Price per share for each share of Preferred Stock then so held, plus a further amount equal to any dividends declared but unpaid on such
shares. All of the preferential amounts to be paid to the holders of the Preferred Stock under this Section 2(a)(i) shall be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the
distribution of any assets of this corporation to, the holders of the Common Stock in connection with such Liquidating Transaction. 

 (ii) If, upon such Liquidating Transaction the assets of this corporation are insufficient to
provide for the cash payment of the full aforesaid preferential amounts to the holders of the Preferred Stock, such assets as are available shall be distributed ratably among the holders of the Preferred Stock in proportion to the full preferential
amount each such holder is otherwise entitled to receive. 
 (iii) After payment has been made to the holders of the Preferred Stock of the
full amounts to which they are entitled as provided in Section 2(a)(i) above, the remaining assets of this corporation available for distribution to stockholders shall be distributed pro rata among the holders of Common Stock and
Preferred Stock (on an as-converted to Common Stock basis) until the holders of Preferred Stock have received an amount per share, including the amounts to which they are entitled as provided in Section 2(a)(i) above, equal to three
(3) multiplied by the Original Issue Price per share of such Preferred Stock, for all of such holders’ shares of Preferred Stock (the “Maximum Participation Amount”); provided, however, that the holders of the Preferred
Stock shall be entitled to receive the greater of (x) the Maximum Participation Amount and (y) the amount such holder would have received if all shares of its Preferred Stock had been converted into Common Stock immediately prior to such
distribution. 
 (iv) After payment has been made to the holders of the Preferred Stock in the full amounts to which they are entitled as
provided in Sections 2(a)(i) and 2(a)(iii), any remaining assets or property of this corporation shall be distributed on a pro rata basis among the holders of the Common Stock. 

(v) If any portion of the consideration payable to the stockholders of this corporation is placed into escrow and/or is payable to the
stockholders of this corporation subject to contingencies, the agreement governing such transaction shall provide that (x) the portion of such consideration that is not placed in escrow and not subject to any contingencies (the “Initial
Consideration”) shall be allocated among the holders of capital stock of this corporation in accordance with the liquidation preference order as set forth in this Section 2 as if the Initial Consideration were the only
consideration payable in connection with such Liquidating Transaction and (y) any additional consideration which becomes payable to the stockholders of this corporation upon release from escrow or satisfaction of contingencies shall be
allocated among the holders of capital stock of this corporation in accordance with the liquidation preference order as set forth in this Section 2 after taking into account the previous payment of the Initial Consideration as part of
the same transaction. 
 For purposes of this Section 2, a “Liquidating Transaction” of this corporation shall
mean a (i) liquidation, dissolution or winding-up of this corporation, (ii) sale, conveyance, license or other disposition of all or substantially all of the assets, property or business of this corporation, or, (iii) merger or
consolidation with or into any other corporation. 
 (b) Notice of Liquidating Transaction. This corporation shall give each
holder of record of Preferred Stock written notice of any impending Liquidating Transaction not later than ten (10) days prior to the stockholders’ meeting called to approve such Liquidating Transaction, or ten (10) days prior to the
closing of such Liquidating Transaction, whichever is earlier, and shall also notify such holders in writing of the final approval of such Liquidating Transaction. The first of such notices shall describe the material terms and conditions of the
impending Liquidating Transaction and the provisions of this Section 2, and this corporation shall thereafter give such holders prompt notice of any material changes. Unless such notice 

 
requirements are waived, the Liquidating Transaction shall not take place sooner than ten (10) days after this corporation has given the first notice provided for herein or sooner than ten
(10) days after this corporation has given notice of any material changes provided for herein. Notwithstanding the other provisions of this Certificate of Incorporation, all notice periods or requirements in this Certificate of Incorporation
applicable to the holders of Preferred Stock may be shortened or waived, either before or after the action for which notice is required, upon the written consent of the holders of at least sixty percent (60%) of the voting power of the
outstanding shares of Preferred Stock that are entitled to such notice rights. 
 (c) Consent for Certain Repurchases. Each
holder of an outstanding share of Preferred Stock shall be deemed to have consented, for purposes of Section 160 of the General Corporation Law of the State of Delaware (and, if applicable, Sections 502, 503 and 506 of the California
Corporations Code), to distributions made by this corporation in connection with the repurchase of shares of Common Stock issued to or held by employees or consultants upon termination of their employment or services pursuant to agreements providing
for the right of said repurchase between this corporation and such persons but only to the extent each distribution equals the original purchase price of such shares being repurchased. 

3. Voting Rights. 
 (a)
The Series A Preferred Stock, voting as a separate class, shall be entitled to elect three (3) members of the board of directors (the “Series A Directors”), the Common Stock, voting as a separate class, shall be entitled to
elect two (2) members of the board of directors (the “Common Directors”), the holders of a majority of the Common Stock and a majority of the Series A/A-1 Preferred Stock, each voting as a separate class on an as converted
basis, shall be entitled to elect one (1) member, and the holders of at least sixty percent (60%) of the Series A/A-1 Preferred Stock and a majority of the Common Stock, each voting as a separate class, shall be entitled to elect any
remaining directors. 
 (b) On all other matters, except as specifically provided herein or as otherwise required by law, holders of the
Preferred Stock shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall be entitled to vote, together with the holders of Common Stock, with respect to any matters upon which holders
of Common Stock have the right to vote. Except as otherwise provided herein, the holder of each share of Common Stock issued and outstanding shall have one vote and the holder of each share of Preferred Stock shall be entitled to the number of votes
equal to the largest number of shares of Common Stock into which such share of Preferred Stock could be converted at the record date for determination of the stockholders entitled to vote on such matters, or, if no such record date is established,
at the date such vote is taken or any written consent of stockholders is solicited, such votes to be counted together with all other shares of stock of this corporation having general voting power and not separately as a class. For purposes of this
Section 3, the “voting power of the shares of Preferred Stock” shall mean the number of votes equal to the number of shares of Common Stock into which such shares of Preferred Stock could be converted at the dates provided in
the preceding sentence. Fractional votes by the holders of Preferred Stock shall not, however, be permitted and any fractional voting rights shall (after aggregating all shares into which shares of Preferred Stock held by each holder could be
converted) be rounded to the nearest whole number. 
 4. Conversion. The holders of the Preferred Stock shall have conversion rights
as follows (the “Conversion Rights”): 

 (a) Right to Convert. Each share of Preferred Stock shall be convertible into
shares of Common Stock without the payment of any additional consideration by the holder thereof and, at the option of the holder thereof, at any time after the date of issuance of such share, at the office of this corporation or any transfer agent
for the Preferred Stock and shall be convertible into the number of fully paid and nonassessable shares of Common Stock which results from dividing the Conversion Price (as hereinafter defined) per share in effect for each series of Preferred Stock
at the time of conversion into the per share Conversion Value (as hereinafter defined) of such series. The initial per share Conversion Price of the Series A Preferred Stock shall be Ninety-One Cents ($0.91). The per share Conversion Value of the
Series A Preferred Stock shall be Ninety-One Cents ($0.91) (as adjusted for stock splits, stock dividends, recapitalization and similar events relating to the Series A Preferred Stock). The initial per share Conversion Price of the Series A-1
Preferred Stock shall be determined in accordance with Section 4(g) hereof. The per share Conversion Value of the Series A-1 Preferred Stock shall be Ninety One Cents ($0.91) (as adjusted for stock splits, stock dividends,
recapitalization and similar events relating to the Series A Preferred Stock and Series A-1 Preferred Stock). The initial per share Conversion Price of the Series B Preferred Stock shall be Ninety-One Cents ($0.91). The per share Conversion Value of
the Series B Preferred Stock shall be Ninety-One Cents ($0.91) (as adjusted for stock splits, stock dividends, recapitalization and similar events relating to the Series B Preferred Stock). The initial Conversion Price of the Series A Preferred
Stock, the Series A-1 Preferred Stock and the Series B Preferred Stock shall be subject to adjustment from time to time as provided below, subject to the terms of Section 4(g) hereof The number of shares of Common Stock into which a
share of Preferred Stock is convertible is hereinafter referred to as the “Conversion Rate” of such series. 
 (b)
Automatic Conversion. Each share of Preferred Stock shall automatically be converted into share(s) of Common Stock at its then effective Conversion Rate of such series of Preferred Stock immediately upon the earlier of (i) the closing of
the sale of this corporation’s Common Stock in a firm commitment, underwritten public offering registered under the Securities Act of 1933, as amended (“Securities Act”), with aggregate offering proceeds to this corporation
(before deduction for underwriters’ discounts and expenses relating to the issuance) of at least Fifty Million Dollars ($50,000,000) and a public offering price per share equal to at least three (3) times the Original Issue Price for the
Series A Preferred Stock, or (ii) at the election of the holders of at least sixty percent (60%) of the outstanding shares of the Series A/A-1 Preferred Stock voting together as a single class on an as-converted basis. 

(c) Mechanics of Conversion. Before any holder of Preferred Stock shall be entitled to convert the same into shares of Common
Stock, the holder shall surrender the certificate(s) therefor, duly endorsed, at the office of this corporation or of any transfer agent for the Preferred Stock and shall give written notice to this corporation at such office that the holder elects
to convert the same (except that no such written notice of election to convert shall be necessary in the event of an automatic conversion pursuant to Section 4(b) hereof). This corporation shall, as soon as practicable thereafter, issue
and deliver at such office to such holder of Preferred Stock certificate(s) for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed to have been made immediately prior to the
close of business on the date of such surrender of the shares of Preferred Stock to be converted (except that in the case of an automatic conversion pursuant to Section 4(b)(i) hereof such conversion shall be deemed to have been made
immediately prior to the closing of the offering referred to in Section 4(b)(i)) or in the case of an automatic conversion pursuant to Section 4(b)(ii) hereof, immediately prior to the close of business on the date of the
election referred to in Section 4(b)(ii) and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes 

 
as the record holder or holders of such shares of Common Stock on such date. If the conversion is in connection with an underwritten public offering of securities registered pursuant to the
Securities Act, the conversion may, at the option of any holder tendering such Preferred Stock for conversion, be conditioned upon the closing with the underwriters of the sale of securities pursuant to such offering, in which event any persons
entitled to receive Common Stock upon conversion of such Preferred Stock shall not be deemed to have converted such Preferred Stock until immediately prior to the closing of such sale of securities. 

(d) Fractional Shares. In lieu of any fractional shares to which the holder of Preferred Stock would otherwise be entitled, this
corporation shall pay cash equal to such fraction multiplied by the fair market value of one share of such series of Preferred Stock as determined by the board of directors of this corporation. Whether or not fractional shares are issuable upon such
conversion shall be determined on the basis of the total number of shares of Preferred Stock of each holder at the time converting into Common Stock and the number of shares of Common Stock issuable upon such aggregate conversion. 

(e) Adjustment of Conversion Price. The Conversion Price of the Series A Preferred Stock (“Series A Conversion
Price”) and the Conversion Price of the Series B Preferred Stock (“Series B Conversion Price”) shall each be subject to independent adjustment from time to time as follows: 

(i) Definitions. For purposes of this paragraph 4(e), the following definitions shall apply: 

(A) “Excluded Stock” shall mean: 

(1) all shares of Common Stock issued or deemed issued to officers, directors, consultants or employees of this corporation, pursuant to a
stock option plan or other agreement approved by a majority of the board of directors of this corporation; 
 (2) all shares of Common Stock
issued or deemed issued in connection with research and development partnerships, licensing, corporate partnering, collaborative arrangements or similar transactions approved by the holders of at least sixty percent (60%) of the outstanding
Preferred Stock; 
 (3) all securities issued pursuant to dividends or distributions on the Preferred Stock; 

(4) securities to financial institutions or lessors issued in connection with commercial credit arrangements, equipment financings, commercial
property lease transactions, or similar transactions approved by a majority of the board of directors of this corporation; 
 (5) capital
stock issued in connection with bona fide acquisitions, mergers, consolidations or similar business combinations, provided that such issuance has been approved by the holders of at least sixty percent (60%) of the outstanding Preferred Stock;

 (6) Common Stock issuable upon conversion of the Preferred Stock; 

 (7) Series A-1 Preferred Stock issued upon conversion of the Series A Preferred Stock; 

(8) Series B Preferred Stock issued upon conversion of notes issued by this corporation pursuant to that certain Note Purchase Agreement, by
and among this corporation and certain other parties, dated on or about even date herewith (the “2012 Note Purchase Agreement”), which notes do not represent debt in excess of $750,000 in the aggregate; 

(8) (i) warrants to purchase Series A Preferred Stock (the “Series A Warrants”) issued in connection with the Purchase
Agreement (as defined below) and (ii) warrants to purchase Common Stock issued pursuant to (a) that certain Note and Warrant Purchase Agreement dated August 3, 2010, by and among this corporation and certain other parties as amended
from time to time, and (b) that certain Note and Warrant Purchase Agreement dated December 20, 2011, by and among this corporation and certain other parties, as amended from time to time (the “2011 Note and Warrant Purchase
Agreement”) (collectively, the “Common Stock Warrants”); and 
 (9) (i) Series A Preferred Stock issued upon
exercise of the Series A Warrants, (ii) Common Stock issued upon exercise of the Common Stock Warrants; and (iii) any shares of this corporation’s capital stock issuable upon conversion of such shares of capital stock. 

(B) “Options” means options to purchase or rights to subscribe for Common Stock (other than Excluded Stock). 

(C) “Convertible Securities” means securities by their terms directly or indirectly convertible into or exchangeable
for Common Stock (other than Excluded Stock) and options to purchase or rights to subscribe for such convertible or exchangeable securities. 

(D) “Purchase Rights” means Options and Convertible Securities. 

(E) “Dilutive Issuance” means an issuance of Purchase Rights, or Common Stock which is not Excluded Stock, without
consideration or for a consideration per share less than the applicable Conversion Price. “Dilutive Issuance” excludes any stock dividend, subdivision or split-up, stock combination, dividend or Transaction described in Sections
4(e)(iv) through (vii) below. 
 (ii) Adjustment of Conversion Price for Dilutive Issuances of Series A Preferred
Stock. If this corporation issues or is deemed to issue any Common Stock in a Dilutive Issuance, the Series A Conversion Price in effect after each such issuance shall be adjusted to a price determined by multiplying the Series A Conversion
Price in effect immediately prior to the Dilutive Issuance by a fraction: 
 (A) the numerator of which shall be (1) the number of
shares of Common Stock outstanding and issuable on exercise of all outstanding Options and Convertible Securities immediately prior to the Dilutive Issuance, plus (2) the number of shares of Common Stock that the aggregate consideration, if
any, received by this corporation in connection with the Dilutive Issuance would purchase at such Conversion Price, and 

 (B) the denominator of which shall be (1) the number of shares of Common Stock outstanding
and issuable on exercise of all outstanding Options and Convertible Securities immediately prior to the Dilutive Issuance, plus (2) the number of shares of Common Stock issued or deemed issued in the Dilutive Issuance. 

(iii) For purposes of any adjustment of the Series A Conversion Price pursuant to clause (ii) above, the following provisions shall be
applicable: 
 (A) In the case of the issuance of Common Stock for cash, the consideration shall be deemed to be the amount of cash paid
therefor after deducting any discounts or commissions paid or incurred by this corporation in connection with the issuance and sale thereof 

(B) In the case of the issuance of Common Stock for a consideration in whole or in part other than cash, the consideration other than cash
shall be deemed to be the fair market value thereof as determined by the board of directors of this corporation, in accordance with generally accepted accounting treatment; provided, however, that if at the time of such determination, this
corporation’s Common Stock is traded in the over-the-counter market or on a national or regional securities exchange, such fair market value as determined by the board of directors of this corporation shall not exceed the aggregate
“Current Market Price” (as defined below) of the shares of Common Stock being issued. 
 (C) In the case of the issuance of
Purchase Rights in a Dilutive Issuance: 
 (1) the aggregate maximum number of shares of Common Stock deliverable upon exercise of Options
shall be deemed to have been issued at the time such Options were issued and for a consideration equal to the consideration (determined in the manner provided in (iii) (A) and (B) above), if any, received by this corporation upon the
issuance of such Options plus the minimum purchase price provided in such Options covered thereby; 
 (2) the aggregate maximum number of
shares of Common Stock deliverable upon conversion or exercise of or exchange for any Convertible Securities shall be deemed to have been issued at the time such Convertible Securities were issued and for a consideration equal to the consideration
received by this corporation for any such Convertible Securities (excluding any cash received on account of accrued interest or accrued dividends), plus the minimum additional consideration, if any; to be received by this corporation upon the
conversion or exchange of such Convertible Securities (determined in the manner provided in (iii) (A) and (B) above); 
 (3)
on any change in the number of shares of Common Stock deliverable upon exercise of any such Purchase Rights or on any change in the minimum purchase price of such Purchase Rights, the Series A Conversion Price shall forthwith be readjusted to such
Series A Conversion Price as would have been obtained had the adjustment made upon (x) the issuance of such Purchase Rights not exercised, converted or exchanged prior to such change, as the case may be, been made upon the basis of such change
or (y) the issuance of options or rights related to such securities not converted or exchanged prior to such change, as the case may be, been made upon the basis of such change; and 

 (4) on the expiration of any Purchase Rights, the Series A Conversion Price shall forthwith be
readjusted to such Series A Conversion Price as would have obtained had the adjustment made upon the issuance of such Purchase Right been made upon the basis of the issuance of only the number of shares of Common Stock actually issued upon the
exercise of such Purchase Rights. 
 (iv) If the number of shares of Common Stock outstanding at any time after the date this Certificate of
Incorporation is filed with the Secretary of State of the State of Delaware (the “Filing Date”) is increased by a stock dividend payable in shares of Common Stock or by a subdivision or split-up of shares of Common Stock, then, on
the date such payment is made or such change is effective, the applicable Conversion Price shall be appropriately decreased so that the number of shares of Common Stock issuable on conversion of any shares of such Preferred Stock shall be increased
in proportion to such increase of outstanding shares. 
 (v) If the number of shares of Common Stock outstanding at any time after the
Filing Date is decreased by a combination of the outstanding shares of Common Stock then, on the effective date of such combination, the applicable Conversion Price shall be appropriately increased so that the number of shares of Common Stock
issuable on conversion of any shares of Preferred Stock shall be decreased in proportion to such decrease in outstanding shares. 
 (vi) In
case this corporation shall declare a cash dividend upon its Common Stock payable otherwise than out of retained earnings or shall distribute to holders of its Common Stock shares of its capital stock (other than Common Stock); stock or other
securities of other persons, evidences of indebtedness issued by this corporation or other persons, assets (excluding cash dividends) or options or rights (excluding Purchase Rights), then, in each such case, the holders of shares of Preferred Stock
shall, concurrent with the distribution to holders of Common Stock, receive a like distribution based upon the number of shares of Common Stock into which each series of Preferred Stock is convertible. 

(vii) In case, at any time after the date hereof, of any capital reorganization, or any reclassification of the stock of this corporation
(other than as a result of a stock dividend or subdivision, split-up or combination of shares provided for under Section 4(e)(iv) or (v) above), or the consolidation or merger of this corporation with or into another person
(other than a consolidation or merger in which this corporation is the continuing entity and which does not result in any change in the Common Stock), or of the sale or other disposition of all or substantially all the properties and assets of this
corporation (“Transaction”), the shares of Preferred Stock shall, after such Transaction, be convertible into the kind and number of shares of stock or other securities or property of this corporation or otherwise to which such
holder would have been entitled if immediately prior to such Transaction the holder had converted the holder’s shares of Preferred Stock into Common Stock. The provisions of this clause (vii) shall similarly apply to successive
Transactions. 
 (viii) All calculations under this Section 4 shall be made to the nearest cent or to the nearest 1/100 of a
share, as the case may be. 
 (ix) For the purpose of any computation pursuant to this Section 4(e), the “Current Market
Price” at any date of one share of Common Stock, shall be deemed to be the average of the highest reported bid and the lowest reported offer prices on the preceding business day as reported by Nasdaq (or equivalent recognized source of
quotations); provided, however, that if the 

 
Common Stock is not traded in such manner that the quotations referred to in this clause (ix) are available for the period required hereunder, Current Market Price shall be determined in
good faith by the board of directors of this corporation. 
 (f) Minimal Adjustments. No adjustment in the Conversion Price need be
made if such adjustment would result in a change in the Conversion Price of less than $0.01. Any adjustment of less than $0.01 which is not made shall be carried forward and shall be made at the time of and together with any subsequent adjustment
which, on a cumulative basis, amounts to an adjustment of $0.01 or more in the Conversion Price. 
 (g) Conversion Price of Series
A-1 Preferred Stock. From and after such time as any share of Series A-1 Preferred Stock is issued and outstanding, the Conversion Price for the Series A-1 Preferred Stock shall be the Series A Conversion Price in effect immediately prior to
such issuance and shall not thereafter be subject to adjustment pursuant to Section 4(e) hereof 
 (h) Certificate as
to Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Rate pursuant to this Section 4, this corporation at its expense shall promptly compute such adjustment or readjustment in accordance with the
terms hereof and prepare and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which adjustment or readjustment is based. This corporation shall, upon request
at any time of any holder of Preferred Stock, furnish or cause to be furnished to such holder a like certificate setting forth (i) such adjustments and readjustments, (ii) the Conversion Rate at the time in effect, and (iii) the
number of shares of Common Stock and the amount, if any, of other property which at the time would be received upon the conversions of such holder’s shares of Preferred Stock. 

(i) Notices of Record Date. In the event of any taking by this corporation of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend) or other distribution, any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other
securities or property or to receive any other right, this corporation shall mail to each holder of Preferred Stock at least twenty (20) days prior to such record date, a notice specifying the date on which any such record is to be taken for
the purpose of such dividend or distribution or right, and the amount and character of such dividend, distribution or right. 

Reservation of Stock Issuable Upon Conversion. This corporation shall at all times reserve and keep available out of its authorized but
unissued shares of Common Stock solely for the purpose of effecting the conversion of the shares of Preferred Stock such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares
of Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of Preferred Stock, this corporation will take such corporate action
as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose. 

(k) Notices. Any notice required by the provisions of this Section 4 to be given to the holder of shares of Preferred Stock
shall be deemed given if deposited in the United States mail, postage prepaid, and addressed to each holder of record at such holder’s address appearing on the books of this corporation. 

 5. Special Mandatory Conversions. 

(a) At any time following the date upon which any shares of Series A Preferred Stock were first issued, if (i) any holder of shares of
Series A Preferred Stock is entitled to exercise the right of first offer (the “Right of First Offer”) as set forth in Section 3.1 of that certain Investors’ Rights Agreement, dated as of March 30, 2007, among
this corporation and the holders of the Series A Preferred Stock, as such agreement may from time to time be amended (the “Agreement”), with respect to an equity financing of this corporation in which the purchase price is less than
Ninety-One Cents ($0.91) per share (as adjusted for stock splits, stock dividends, recapitalization and similar events) (which shall not include shares of Series A Preferred Stock offered by this corporation at the Subsequent Closing, as that term
is defined in the Series A Preferred Stock and Warrant Purchase Agreement, dated on or about January 22, 2010, by and among this corporation and the parties thereto (the “Purchase Agreement”), notes issued pursuant to the 2012
Note Purchase Agreement or shares issued upon conversion of such notes) (an “Equity Financing”), (ii) this corporation has complied with its obligations under the Agreement with respect to the Right of First Offer,
(iii) the terms of this Section 5(a) are not waived in writing by the holders of at least sixty percent (60%) of the outstanding shares of Series A Preferred Stock in connection with such Equity Financing and (iv) such
holder does not by exercise of such holder’s Right of First Offer acquire the minimum amount of Offered Securities (defined below) to which such holder is entitled pursuant to Section 3.1 of the Agreement or such lesser amount of
securities (the “Threshold Amount”) agreed to in writing by this corporation and holders of at least sixty percent (60%) of the outstanding shares of Series A Preferred Stock (excluding for this purpose any shares held by such
holder), then all of such holder’s shares of Series A Preferred Stock shall automatically and without further action on the part of such holder be converted into an equivalent number of shares of Series A-1 Preferred Stock effective immediately
prior to the consummation of such Equity Financing. “Offered Securities” means the equity securities of this corporation set aside by the board of directors of this corporation for purchase by holders of outstanding shares of Series
A Preferred Stock in connection with an Equity Financing, and offered to such holders. For purposes of this Section 5(a), a holder and its Affiliates (as defined in the Agreement) shall, at the election of such holder, be treated as an
Investor Group (as defined in the Agreement) and may reallocate the Right of First Offer among themselves as they determine. Notwithstanding the foregoing, to the extent that a holder purchases some securities in an Equity Financing but not an
amount equal to the Threshold Amount, only a Pro-rata Portion (as defined below) of such holder’s shares shall be converted into shares of Series A-1 Preferred Stock. “Pro-rata Portion” shall be equal to the percent of such
holder’s Threshold Amount the holder does not purchase. The conversion provided for in this Section 5(a) shall not occur in connection with a particular Equity Financing if, pursuant to the written request of this corporation, the
Right of First Offer with respect to such Equity Financing is waived in accordance with the terms of the Agreement. Upon conversion pursuant to this Section 5, the shares of Series A Preferred Stock so converted shall be canceled and not
subject to reissuance. 
 (b) At any time following the filing and acceptance of this Amended and Restated Certificate of Incorporation, if
any holder of more than one percent (1%) of the outstanding Series A/A-1 Preferred Stock (a “Major Preferred Stockholder”) does not (either individually or through its affiliates) fund any portion of its Required Initial
Closing Pro Rata Share (as defined in 2011 Note and Warrant Purchase Agreement) at the Initial Closing (as defined in 2011 Note and Warrant Purchase Agreement) (a “Non-Participating Initial Closing Holder”) pursuant to the 2011 Note
and Warrant Purchase Agreement, then a proportionate share of such Non-Participating Initial Closing Holder’s shares of Series A/A-1 Preferred Stock equal to any such deficiency shall automatically and without further action on the part of such
Non-Participating Initial Closing Holder be, effective 

 
immediately prior to, but subject to, the consummation of the Initial Closing, converted into Common Stock at the then effective Conversion Price for each series of Series A/A-1 Preferred Stock
held by such Non-Participating Initial Closing Holder. Upon conversion pursuant to this Section 5(b), the shares of Series A/A-1 Preferred Stock so converted shall be cancelled and not subject to reissuance. 

(c) At any time following the filing and acceptance of this Amended and Restated Certificate of Incorporation, if any Major Preferred
Stockholder does not (either individually or through its affiliates) fund any portion of its Required Additional Closing Pro Rata Share (as defined in 2011 Note and Warrant Purchase Agreement) at the Additional Closing (as defined in 2011 Note and
Warrant Purchase Agreement) (a “Non-Participating Additional Closing Holder”) pursuant to the 2011 Note and Warrant Purchase Agreement, then a proportionate share of such Non-Participating Additional Closing Holder’s shares of
Series A/A-1 Preferred Stock equal to any such deficiency shall automatically and without further action on the part of such Non-Participating Additional Closing Holder be, effective immediately prior to, but subject to, the consummation of the
Additional Closing, converted into Common Stock at the then effective Conversion Price for each series of Series A/A-1 Preferred Stock held by such Non-Participating Additional Closing Holder. Upon conversion pursuant to this
Section 5(c), the shares of Series A/A-1 Preferred Stock so converted shall be cancelled and not subject to reissuance. 
 (d)
The holder of any shares of Series A/A-1 Preferred Stock converted pursuant to Section 5(a), Section 5(b) or Section 5(c) hereof shall deliver to this corporation during regular business hours at the office of any
transfer agent of this corporation for such series of Series A/A-1 Preferred Stock, or at such other place as may be designated by this corporation, the certificate or certificates representing the shares so converted, duly endorsed or assigned in
blank or to this corporation, or a reasonably acceptable affidavit and indemnity undertaking in the case of a lost, stolen or destroyed certificate. As promptly thereafter as is practicable, this corporation shall issue and deliver to such holder,
at the place designated by such holder, a certificate or certificates for the number of full shares of the Series A-1 Preferred Stock or Common Stock to which such holder is entitled pursuant to Section 5(a), Section 5(b) or
Section 5(c) hereof, as applicable. The person in whose name the certificate for such shares of Series A1 Preferred Stock or Common Stock, as applicable, is to be issued shall be deemed to have become a stockholder on the effective date
of the conversion of the Series A/A-1 Preferred Stock, unless the transfer books of this corporation are closed on that date, in which case such person shall be deemed to have become a stockholder of record on the next succeeding date on which the
transfer books are open. 
 (e) This corporation shall not issue any shares of Series A-1 Preferred Stock except pursuant to and in
accordance with this Section 5. 
 6. Protective Provisions. So long as at least One Million (1,000,000) shares of Series
A/A-1 Preferred Stock are outstanding, this corporation shall not (by merger, reclassification or otherwise), without first obtaining the approval (by vote or written consent, as provided by law) of the holders of at least sixty percent
(60%) of the then outstanding shares of Series A/A-1 Preferred Stock voting as a single class: 
 (a) amend the Certificate of
Incorporation or Bylaws to alter or change the rights, preferences or privileges of the Preferred Stock; 

 (b) increase or decrease the aggregate number of authorized shares of any class of stock; 

(c) increase the number of shares reserved under any stock option plan of this corporation; 

(d) create or effect a creation of any new class or series of shares of stock; 

(e) effect any (i) Liquidating Transaction or (ii) an agreement for the sale of capital stock such that the stockholders immediately
prior to such sale will possess less than fifty percent (50%) of the voting power immediately after such sale; 
 (f) declare or pay
dividends on any capital stock; 
 (g) execute any action to increase or decrease the number of directors of this corporation; 

(h) repurchase or redeem any shares of capital stock except in connection with the repurchase of shares of Common Stock issued to or held by
employees or consultants upon termination of their employment or services pursuant to agreements providing for the right of said repurchase between this corporation and such persons but only to the extent each repurchase equals the original purchase
price of such shares being repurchased; or 
 (i) do any act or thing which would result in taxation of the holders of shares of the
Preferred Stock under Section 305 of the Internal Revenue Code of 1986, as amended (or any comparable provision of the Internal Revenue Code as hereafter from time to time amended). 

ARTICLE VI 
 This
corporation is to have perpetual existence. 
 ARTICLE VII 

1. Limitation of Liability. To the fullest extent permitted by the General Corporation Law of the State of Delaware as the same
exists or as may hereafter be amended, a director of this corporation shall not be personally liable to this corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. 

2. Indemnification. This corporation may indemnify to the fullest extent permitted by law any person made or threatened to be
made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that such person or his or her testator or intestate is or was a director, officer or employee of this corporation, or any
predecessor of this corporation; or serves or served at any other enterprise as a director, officer or employee at the request of this corporation or any predecessor to this corporation. 

3. Amendments. Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of this
corporation’s Certificate of Incorporation inconsistent with this Article VII, shall eliminate or reduce the effect of this Article VII, in respect of any matter 

 
occurring, or any action or proceeding accruing or arising or that, but for this Article VII would accrue or arise, prior to such amendment repeal, or adoption of an inconsistent
provision. 
 ARTICLE VIII 

The shares of Series A Preferred Stock may not be redeemed by this Corporation. In the event that shares of Preferred Stock shall be converted
pursuant to the terms hereof, the shares so converted shall not revert to the status of authorized but unissued shares, but instead shall be canceled and shall not be re-issuable by this corporation. 

ARTICLE IX 
 Holders of
stock of any class or series of this corporation shall not be entitled to cumulate their votes for the election of directors or any other matter submitted to a vote of the stockholders. 

ARTICLE X 
 Elections of
directors need not be by written ballot unless the Bylaws of this corporation so provide. 
 ARTICLE XI 

This corporation hereby renounces, to the fullest extent permitted by Section 122 (17) of the General Corporation Law of the State
of Delaware, any interest or expectancy of this corporation in, or in being offered, an opportunity to participate in, any Series A Business Opportunity. A “Series A Business Opportunity” is any matter, transaction or interest that
is presented to, or acquired, created or developed by, or which otherwise comes into the possession of, (i) any director of this corporation who is not an employee of this corporation or any of its subsidiaries, or (ii) any holder of
Series A Preferred Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee of this corporation or any of its subsidiaries (collectively, “Covered Persons”),
unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of a Covered Person solely in such Covered Person’s capacity as a director of this corporation. To the
fullest extent permitted by law, this corporation hereby waives any claim against a Covered Person, and agrees to indemnify all Covered Persons against any claim, that is based on fiduciary duties, the corporate opportunity doctrine or any other
legal theory which could limit any Covered Person from pursuing or engaging in any Series A Business Opportunity. 
 ARTICLE XII 

In furtherance and not in limitation of the powers conferred by statute, the board of directors of this corporation is expressly authorized to
make, alter, amend or repeal the Bylaws of this corporation. 
 ARTICLE XIII 

The foregoing amendment and restatement of the Certificate of Incorporation has been duly approved by the board of directors of this
corporation. 

 The foregoing Fifth Amended and Restated Certificate of Incorporation has been duly adopted by this
corporation’s Board of Directors and stockholders in accordance with applicable provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware. I further declare under penalty of perjury under the laws of the
State of Delaware that the matters set forth in this certificate are true, correct and of my own knowledge. 
 Dated: October 9, 2012 

 

	
	 /s/ Arlene M. Morris

	Arlene M. Morris,
	Chief Executive Officer

  
 16 

 Exhibit B 

Cash Balance Projection 

  
 Exhibit B 

			
	Syndax Updated Projections	 	Syndax

 Weekly Cash Projections 
  

																																																					
	Weeks	 	1	 	 	2	 	 	3	 	 	4	 	 	5	 	 	6	 	 	7	 	 	8	 	 	9	 	 	 	 	 	10	 	 	11	 	 	12	 
	3/1/2013	 	 	 	 	3/8/2013	 	 	3/15/2013	 	 	3/22/2013	 	 	3/29/2013	 	 	4/5/2013	 	 	4/12/2013	 	 	4/19/2013	 	 	4/26/2013	 	 	Total	 	 	5/3/2013	 	 	5/10/2013	 	 	5/17/2013	 
	 Existing payables*
	 				 	 	439,205	  	 	 	123,775	  	 				 	 	92,719	  	 	 	32,169	  	 	 	<---Excluded from totals*	  	 				 				 				 			
	 Headcount
	 				 				 				 				 				 				 				 				 				 				 				 				 			
	 Payroll
	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 				 	 	40,000	  	 	 	40,000	  	 	 	40,000	  
	 Insurance—health
	 				 	 	12,000	  	 				 				 	 	12,000	  	 				 				 				 	 	12,000	  	 				 				 				 			
	 Insurance—STD/LTD
	 				 	 	1,500	  	 				 				 	 	1,500	  	 				 				 				 	 	1,500	  	 				 				 				 			
	 Insurance—workers comp
	 				 				 				 				 				 				 				 				 	 	3,500	  	 				 				 				 			
	 G&A
	 				 				 				 				 				 				 				 				 				 				 				 				 			
	 Rent
	 				 	 	10,000	  	 				 				 	 	10,000	  	 				 				 				 	 	10,000	  	 				 				 				 			
	 Utilities
	 				 				 				 				 	 	6,300	  	 				 				 				 	 	6,300	  	 				 				 				 			
	 Legal
	 				 				 				 				 	 	15,000	  	 				 				 				 	 	15,000	  	 				 				 				 			
	 Amex/Travel
	 				 	 	2,000	  	 				 				 	 	2,000	  	 				 				 				 	 	2,000	  	 				 				 				 			
	 Drug Manufacture
	 				 				 				 				 	 	135,000	  	 				 				 				 	 	135,000	  	 				 				 				 			
	 Clinical
	 				 				 				 				 				 				 				 				 				 				 				 				 			
	 Study 110/301 costs
	 				 				 				 				 	 	30,000	  	 				 				 				 	 	30,000	  	 				 				 				 			
	 Clin trial insurance
	 				 				 				 				 	 	3,195	  	 				 				 				 				 				 				 				 			
	 GE interest/legal**
	 				 	 	35,000	  	 				 				 	 	35,000	  	 				 				 				 				 				 	 	260,765	  	 				 			
	 Week Total Spend
	 	 	40,000	  	 	 	539,705	  	 	 	40,000	  	 	 	40,000	  	 	 	289,995	  	 	 	40,000	  	 	 	40,000	  	 	 	40,000	  	 	 	255,300	  	 				 	 	300,765	  	 	 	40,000	  	 	 	40,000	  
	 Feb total:
	 	 	40,000	  	 				 				 	 	March total:	  	 	 	909,700	  	 				 				 	 	April total:	  	 	 	375,300	  	 	 	1,325,000	  	 				 				 			
	 Investor funds close 3/1
	 	 	45,000	  	 	 	1,280,000	  	 				 				 				 				 				 				 				 				 				 				 			
	 Cash balance
	 	 	5,000	  	 	 	745,295	  	 	 	705,295	  	 	 	665,295	  	 	 	375,300	  	 	 	335,300	  	 	 	295,300	  	 	 	255,300	  	 	 	0	  	 	 	0	  	 	 	(300,764	) 	 	 	(340,764	) 	 	 	(380,764	) 

  

	*	Past-due payables will be processed on 3/1. Remaining $250K (current payables) will be processed as due, and will be offset by new cost going into payables. 

	**	Assumes 5K legal costs per month 

 $45k in sub debt funded 3/1 by Domain and MPM to fund
payroll and bridge an addt’l week to 3/8. 
 $1.3MM Tr 1 Series B-1 expected to close by 3/8 for runway to Apr ‘13.

 GE to provide month-to-month interest only (initial 2 months) up to 3 months.EX-10.32

 Exhibit 10.32 

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 CLINICAL TRIAL
AGREEMENT 
 This Clinical Trial Agreement (“Agreement”) is entered into as of March 14, 2014 (“Effective
Date”) by and between EASTERN COOPERATIVE ONCOLOGY GROUP, an organization with its executive office at 1818 Market St., Suite 1100, Philadelphia, PA 19103-3602, and its principal place of business at ECOG Coordinating Center, Frontier Science,
900 Commonwealth Avenue, Boston, MA 02215 (“Group”) and Syndax Pharmaceuticals, Inc., a Delaware corporation, with its principal office and place of business located at 400 Totten Pond Road, Suite 140, Waltham, Massachusetts 02451
(“Company”). 
 WITNESSETH 

WHEREAS, the Group and the Company acknowledge and affirm that they are familiar with and understand the U.S. Department of Health and Human
Services and U.S. Food and Drug Administration (“FDA”) regulations governing cooperative group clinical trials and that they are capable of conforming with such regulations; 

WHEREAS, the clinical trial contemplated by this Agreement is of mutual interest and benefit to the Group and to the Company, and will further
the Group’s instructional and research objectives in a manner consistent with its status as a research group; 
 WHEREAS, the Group and
the Company have agreed to enter into this Agreement to set forth the terms pursuant to which the clinical trial shall be performed by the Group and supported in part by the Company; 

NOW THEREFORE, the parties hereto, intending to be legally bound hereby, agree as follows: 

 

	 	1.	CONDUCT OF STUDY 

 A. The Activities. The Group and the Company shall
perform the activities in accordance with the Scope of Work, Exhibit A, for the clinical trial E2112 (EA1122) “A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Post-menopausal Patients with Hormone Receptor-Positive
Advanced Breast Cancer” (the “Study”). The principal investigator (the “Principal Investigator”) for the Group is Robert L. Comis, M.D., assisted by Roisin Connolly, MB, BCh., the study chair (“Study Chair”) for
the Protocol. The Group shall use reasonable efforts to carry out the Study as set forth in the current clinical trial protocol for the Study (the “Protocol”) and in accordance with this Agreement. 

B. IRB. The Group will ensure that the Study begins only after the Group has obtained approval from Institutional Review Board for the
Study (the “IRB”). 
 C. Study Drug. Company agrees that it will provide Group (indirectly through NCI) with the
quantities of the Company’s investigational drug product entinostat and placebo (the “Study Drug”) required to conduct the Study in accordance with the Protocol, at no charge. Group shall use, and will ensure that Study Personnel (as
defined in Section 4.D) 

 
use, the Study Drug solely for purposes of the Study in accordance with the Protocol. In handling, storing and using Study Drug, Group members will comply with all applicable laws and any written
instructions provided by Company (or by NCI on behalf of Company). All Study Drug supplied to Group members will remain the exclusive property of Company until administered or dispensed to any of the patients involved in the Study (“Study
Subjects”) during the course of the Study. Group members will keep the Study Drug in a safe and secure location and maintain complete and accurate records showing disposition of the Study Drug. Group members will not provide access to Study
Drug to anyone except Study Personnel. Group will not chemically, physically or otherwise modify Study Drug. 
 D. Data Protection;
Informed Consent. As applicable, the parties agree to abide by all laws and regulations regarding Study subject privacy and data protection, including without limitation the Health Insurance Portability and Accountability Act of 1996
(“HIPAA”). The Group shall be responsible for ensuring that each Study subject, prior to participation in the Study, signs an informed consent in a form approved by the IRB. Such informed consent shall include a valid authorization,
consistent with HIPAA and all other applicable laws. 
 E. Sponsor. The NCI will be the “Sponsor” of the Study as
such term is defined in FDA regulations, including 21 C.F.R. Parts 312 and 50, and the NCI shall be solely responsible for any and all regulatory obligations associated with such role. 

F. Payment. The Company will provide financial support to the Group in the amount of $19,406,948 in accordance with the payment
schedule and budget set forth in Exhibit B herein. The Company and the Group may, by mutual written agreement, alter the amount or timing of such payments as they deem necessary under the circumstances. Checks shall be made payable to “ECOG
Research and Education Foundation, Inc., agent for Eastern Cooperative Oncology Group.” The Tax Identification number is ***. Checks will reference this Agreement and will be transmitted to ECOG Research and Education Foundation, Inc., Attn:
Donna Marinucci, 1818 Market St., Suite 1100, Philadelphia, PA 19103. 
  

	 	2.	CONFIDENTIAL INFORMATION 

 A. Confidentiality. Except as otherwise provided in
Sections 3 and 4, each party agrees not to disclose or to use for any purpose other than the performance of the Study any and all trade secrets, privileged records or other confidential or proprietary information, data or materials of the other
party (“Proprietary Information”) disclosed by one party or its employees, contractors or agents (“Discloser”) to the other party or its employees, contractors or agents (“Recipient”) pursuant to this Agreement. 

The obligation of non-disclosure and non-use shall not apply to the following: 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 2 

	 	(i)	Proprietary Information at or after such time that it is or becomes publicly available for any reason other than a breach of Recipient’s undertaking hereunder; 

 

	 	(ii)	Proprietary Information that is already independently known to Recipient prior to the date of disclosure of such Proprietary Information to Recipient as evidenced by Recipient’s written records; 

 

	 	(iii)	Proprietary Information that is disclosed to Recipient on a non-confidential basis by a third party that Recipient reasonably believes has the legal right to make such disclosure; or 

 

	 	(iv)	Proprietary Information that is required by law or court order to be disclosed; provided that Recipient: (a) gives Discloser prompt notice of such fact so that Discloser may obtain a protective order or other
appropriate remedy concerning any such disclosure; (b) fully cooperates with Discloser (at Discloser’s sole expense) in connection with Discloser’s efforts to obtain any such order or other remedy; and (c) discloses, when
disclosure is necessary, only the minimum information legally required to be disclosed in order to comply, whether or not a protective order or other similar order is obtained by Discloser. 

B. Terms of Non-Disclosure. The obligations of this Section shall survive and continue for *** years after termination of
this Agreement. 
 C. Identity of Study Subjects. In the event the Company or its employees, contractors or agents shall come
into contact with records identifying in any manner any of the patients involved in the Study (“Study Subjects”), the Company shall hold such identifying information in confidence, agrees not to use or disclose such information and shall
immediately delete the identifying information. 
 D. Limited Disclosure. In the event that either party finds it necessary to
disclose Proprietary Information of the other party to a proper authority to permit such party to defend itself, such party shall first notify the other party and the parties shall agree to a mutually satisfactory way to disclose such information as
necessary for this limited purpose. 
  

	 	3.	PUBLICATIONS/PRESENTATIONS 

 A. Disclosure of Data. Data generated by the Study
(“Data”) is the sole property of the Group and shall be considered as Group Proprietary Information. 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 3 

 B. Publication of Study Results. The Company recognizes that under the Group
policy, the results of the Study must be published and agrees that researchers engaged in the Study reserve the right, and are entitled, to present and publish Data at symposia, national or regional professional meetings, and to publish in a journal
or otherwise, of their own choosing, methods and results of the Study undertaken under the Agreement, subject to the requirements of this Section 3. 

C. Prior Submissions to the Company. In order to allow the Company to confirm the accuracy of background information, to protect
any patent opportunities, and to review for disclosure of Company Proprietary Information, the Group undertakes to advise its researchers engaged in the Study that manuscripts and abstracts using Data should be submitted through the Group to the
Company as follows: 
  

	 	(1)	for manuscripts, no less than *** days prior to submission of a manuscript for publication, and 

  

	 	(2)	for abstracts routinely submitted in advance of a meeting or conference, whether or not made available in print or electronically in advance of a meeting, a reasonably complete_draft of it no less than *** days before
the meeting submission deadline, and 

  

	 	(3)	for abstracts of late-breaking trial results or otherwise submitted to a meeting or conference after the routine deadline, as soon as practicable and in no event less than *** days before its anticipated presentation.

 The Group shall use reasonable, diligent efforts to ensure that such researchers comply with the foregoing submission requirements. At
Company’s written request, the Group will delete any of the Company’s Proprietary Information included in the presentation or publication. With respect to a manuscript, in the event that the Company elects to take patent action, the Group
agrees to delay submission for an additional *** days. In such event with respect to an abstract, the Group and the Company will in good faith attempt to reach an equitable solution to the Company’s concern. Additionally, the Group agrees to
work in good faith with the Company to ensure that the timing of any presentation or publication does not comprise any then-pending regulatory approval of a product containing the Study Drug. For the purpose of compliance with this Section 3, a
draft manuscript or abstract may be submitted to the Company provided that the Company receives a final manuscript as soon as practicable thereafter. 
  

	 	4.	DATA AND OTHER RIGHTS 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 4 

 A. No Group Rights in Study Drug. Neither the Group nor any Member of the Group nor
any Principal Investigator shall acquire any rights of any kind in the Study Drug as a result of participation in the Study. 
 B.
Data. The Company acknowledges and agrees that all Data shall be owned exclusively by the Group, subject to Company’s rights as provided below. NCI will furnish data to Company required pursuant to the Collaborative Agreement between
Company and the NCI Division of Cancer Treatment and Diagnosis for the Study Drug. Additionally, the Group will provide Company with the Data-related deliverables set forth in Exhibit A. The timing of the Group’s delivery of such deliverables
to Company shall be governed by a separate data transfer plan (the “Data Transfer Plan”) that will be separately negotiated by Company and the Group in good faith following the Effective Date, taking into account the deadlines and other
requirements imposed on the Company in connection with the regulatory approval process for the Study Drug. The parties agree that the Data Transfer Plan must be completed and executed by the parties on or before ***. The Group will be reasonably
compensated for costs associated with satisfying any request that Data be provided in a format that is different than the format used by the Group. The Group hereby grants Company and its affiliates a fully paid-up, royalty-free, non-exclusive,
perpetual, irrevocable, worldwide license to use the Data for any purpose permitted by applicable law, rule or regulation, including submission to FDA in support of regulatory applications. This license will be sublicensable and freely transferable
by Company and its affiliates. The foregoing is not intended to grant any rights in inventions, which are addressed in Section 4.D below. The Group shall ensure that all Members and Member Institutions (as defined below) participating in the
Study provide Company with access to, and the right to use, Data in accordance with this Section. Consistent with the National Cancer Institute (“NCI”) Policy Statement entitled “NCI – Cooperative Group – Industry
Relationship Guidelines” (http://ctep.cancer.gov/industryCollaborations2/guidelines.htm), Data deliverables set forth in Exhibit A shall be provided by the Group to the Company, NCI, and/or FDA, as appropriate. 

C. Study Records. In the event the Company believes in good faith that the Group has materially failed to comply with applicable laws,
or in the event required by regulatory authorities, or to defend any claim or action against the Company, Study records (other than those to be provided in accordance with the Agreement) shall be made reasonably available to the Company for
inspection during normal business hours; provided however, that (1) the records may be located at individual Member Institutions; (2) access to the records will be subject to the respective operating procedures of the individual
institutions; and (3) the Company may be required to reimburse the Group and/or Member Institutions for reasonable time cost and expense (which may include without limitation, staffing and internal costs and expense) necessary to provide such
access. 
 D. For purposes of this Agreement, the terms “Member Institution” and “Member” shall be defined to
include institutions and individual researchers who are main or affiliate members of the Group, and member institutions and individual researchers of 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 5 

 
other cooperative groups through the NCI Cancer Trials Support Unit (CTSU). The Company acknowledges and agrees that Member Institutions and Members participating in the Study are third-party
beneficiaries to this Agreement, and, as such, are entitled to all of the rights and obligations accruing to such party hereunder and thereunder. For purposes of this Agreement, “Study Personnel” shall mean the Principal Investigator, the
Study Chair, and such other employees, staff, agents, affiliates and permitted subcontractors of Group and each Member Institution, in each case that are participating in the conduct of the Study. 

E. For purposes of this Section 4, “Company” shall be defined as including any corporation or other business entity
controlled by, controlling, or under common control with the Company. For this purpose, “control” means (i) direct or indirect beneficial ownership of fifty percent (50%) or more of the voting control, or (ii) the power to
direct or cause the direction of the management and policies of such corporation or other business entity. 
 F. Company will keep
the Group reasonably informed of Company’s plans for submission of any clinical study report that includes or refers to any Data that it intends to submit to the FDA or other regulatory authority, and will provide a minimum of *** days notice
to Group prior to sending the initial draft of any such clinical study report . Group shall be afforded the right to conduct a complete, accurate, and timely review and provide comments on any clinical study report that Company prepares for
submission to the FDA or other regulatory authority that includes or refers to any Data. The Group will provide Company with comments on the initial draft submission no later than *** calendar days after receiving it. Company will promptly provide
the Group with any subsequent draft submission versions through the final submission for review, and the Group will provide comments on revised draft submissions through the final submission within *** calendar days of receipt. The Company will use
best efforts to address the Group’s comments. Company shall ensure that there is sufficient time to ensure submissions to the FDA or other regulatory authority and to address the Group’s comments. Within *** business days of the
Group’s comments to each submission, at the request of either party, the parties agree to meet in person or by conference call to discuss in good faith Group’s comments and the course of action to be taken by Company concerning
Group’s comments. The parties agree to provide promptly any correspondence received from the FDA through NCI as IND holder. Notwithstanding this Section 4.F, Group shall have the right, at any time after Group receives an analysis from
Company, to submit an analysis of the same data or other material independently to the FDA (including but not limited to a separate analysis of the submissions referenced therein,) after giving *** calendar days notice. 

G. Inventions. The Group shall own all of its inventions resulting from its performance of the Study. “Study Drug Invention”
shall mean any discovery or invention conceived or reduced to practice by the Group that is derived from the Study Drug as a result of using the Study Drug during the Study, including, but not limited to, new uses, processes, derivatives,
formulations or therapeutic combinations of the Study Drug. The Group shall promptly notify the Company in writing of any Study Drug Inventions made by the Group solely 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 6 

 
in connection with the Study and hereby grants the Company a royalty-free, fully paid-up, non- exclusive license in such Study Drug Inventions (which may be sublicensed by Company provided that
such sublicense(s) are granted in conjunction with licenses to Company’s other rights in the Study Drug). The Group also grants the Company a first right to negotiate an exclusive, worldwide license, with the right to sublicense, in any and all
Study Drug Inventions. Any first option must be exercised by the Company within *** after receiving notice of any Study Drug Inventions and, upon the exercise of such option by the Company, the exclusive license agreement for any Study Drug
Inventions must be completed by the parties within *** (which period may be extended by mutual agreement of the parties). The Group shall retain a non- exclusive license to any Study Drug Invention solely for non-commercial research, education and
patient care purposes. The Group shall ensure that all Members and Member Institutions participating in the Study provide Company with invention rights that are substantially similar to those set forth in this Section. 

 

	 	5.	USE OF THE GROUP’S OR THE COMPANY’S NAME 

 A. Use of Names. The Group,
on one hand, and the Company, on the other hand, will obtain prior written permission from the other before using the name, symbols and/or marks of the other or its employees, agents or contractors in any form of publicity in connection with the
Study, which permission shall not be unreasonably withheld, and provided that this Section 5.A shall not apply to use by the Group of any name of the Study Drug, whether or not trademarked by the Company, in connection with Study materials,
provided that such use is otherwise in accordance with applicable laws and regulations. To the extent either party permits such use of its name, symbols and/or marks by the other party, such permitted use shall not be deemed to grant any license or
other right in any such name, symbol or mark unless expressly so provided as a provision of a written agreement signed by both parties. The obligations of this Section shall not apply to (i) legally required disclosures by the Group or the
Company ; (ii) a statement by either the Company or the Group indicating the existence of this Agreement and/or either party’s involvement in the Study; and (iii) the publication of information that is already publicly available. 

B. No Endorsement. The Company will not use, nor authorize others to use, the name, symbols, or marks of the Group, of any Member
Institution or of any Member or their respective employees, agents or contractors in any advertising or publicity material or make any form of representation or statement in relation to the Study which would constitute an express or implied
endorsement by the Group, any Member Institution or any Member of any commercial product or service without prior written approval from the Group, the Member Institution or the Member. 

C. Clinical Trial Registry. The parties shall cooperate as necessary with the National Cancer Institute to have the Study registered
with the ClinicalTrials.gov website of the U.S. National Institutes of Health (or any successor thereto) before enrollment of patients for such Study. 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 7 

	 	6.	APPLICABLE LAW 

 This Agreement shall be governed by the laws of the Commonwealth of
Pennsylvania. 
  

	 	7.	INDEMNIFICATION 

 A. Company’s Indemnification. The Company shall defend,
indemnify and hold harmless the Group, Member Institutions and Members and each of their respective agents, employees, contractors, directors and officers and their respective successors, assigns, personal representatives and heirs (collectively,
the “Group Indemnitees”) from any and all liabilities, expenses (including reasonable attorney fees), or fines or other levies from governmental or regulatory agencies (collectively, “Indemnifiable Losses”) incurred by an Group
Indemnitee in connection with a claim, action or suit by a third party (including but not limited to those arising from personal injury or death), to the extent arising from or relating to (1) any manufacturing defect in or instructions for use
of, the Study Drug provided by Company; (2) any negligent or willful act or omission by a Company Indemnitee in the performance of Company’s obligations hereunder or under the Study; or (3) the use of the Data or the sale or
commercialization of the Study Drug by Company or its licensees; provided, however, but in each case only if the Group promptly notifies the Company in writing of any complaint, claim or injury that could give rise to an Indemnifiable Loss after the
Group has actual knowledge of any such complaint, claim or injury. 
 B. Group’s Liability. The Group shall be responsible and
liable for any claim to the extent arising from or relating to any negligent or willful act or omission by the Group in the performance of Group’s obligations hereunder or under the Study. 

C. Defense of Indemnifiable Losses. The Company shall provide diligent defense against any claims brought or actions filed with respect
to the subject of the indemnity contained herein, whether such claims or actions are rightfully or wrongfully brought or filed. The Company shall have the right to select defense counsel at its own expense, subject to the approval of the Group,
which approval will not unreasonably be withheld, and to direct the defense or settlement of any such claim or suit. The Company upon reasonable prior notice to the Group and any other Group Indemnitees and their respective counsel shall have the
right to settle claims at the Company’s sole expense, but only after consultation with the Group and such Group Indemnitees, provided, however, that no settlement shall contain an admission of liability or negligence of any Group Indemnitees
without the prior written consent of such Group Indemnitees, which consent shall not be unreasonably withheld or delayed. 
 D.
Cooperation. The Group Indemnitees shall reasonably cooperate with the Company and its legal representatives in the investigation and defense of any claim or suit covered under this Agreement. In the event a claim or action is or may be
asserted, the Group Indemnitees shall have the right to select and to obtain representation by separate legal counsel. If any Group Indemnitees exercise such right, all costs and expenses incurred by such

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 8 

 
Group Indemnitees for such separate counsel shall be borne by such Group Indemnitees, except that if such selection of separate legal counsel is based on a written opinion of counsel to any such
Group Indemnitee that such separate legal counsel is required because of actual or potential conflict of interest, the indemnity of this Section 7 shall apply also to the reasonable fees and expenses of such separate legal counsel. The Company
and its counsel shall cooperate with such separate counsel in any investigation, defense or settlement for the purpose of informing and sharing information to enable such separate counsel full participation in any investigation, defense or
settlement. 
 E. Exceptions to Indemnity. Any liability, loss or damage to the extent resulting from gross negligence or willful
malfeasance by an Indemnitee is excluded from the undertakings in this Section 7 to indemnify, defend and hold harmless such Indemnitee. Deviations from the terms of the Protocol that may arise out of clinical or medical necessity do not
constitute gross negligence or willful malfeasance. 
 F. Limitation. IT IS UNDERSTOOD THAT NEITHER PARTY SHALL BE RESPONSIBLE FOR
THE ACTS OR OMISSIONS OF THE OTHER PARTY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY BEFORE OR AFTER TERMINATION OF THIS AGREEMENT UNDER ANY CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INDIRECT, SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING FROM THE PERFORMANCE OF THIS AGREEMENT OR THE STUDY HEREUNDER. 
 G. Reimbursement
of Medical Expenses. The Company shall reimburse the Group for the reasonable and necessary medical expenses incurred by a Study Subject or Member Institution for the diagnosis and treatment of any personal injury relating to (a) the
administration of the Study Drug substantially in accordance with this Agreement, the Protocol, and any other written instructions of the Company or (b) the performance of any test or procedure that is required by such Protocol to which the
Study Subject would not have been exposed but for the Study Subject’s participation in the Study. Notwithstanding the foregoing, the Company shall not be responsible for any portion of such medical expenses that are attributable to the
Group’s breach, negligence or willful misconduct. 
  

	 	8.	TERMINATION 

 A. Unilateral Termination. This Agreement may be terminated by the
Company or the Group, which termination shall be effective no earlier than *** days following receipt of written notice by the non-terminating party, if any of the following conditions shall occur: 

 

	 	(i)	the authorization and approval to perform the Study in the United States is withdrawn by the NCI or FDA; or 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 9 

	 	(ii)	the non-terminating party materially breaches the terms of this Agreement and (1) such breach if a monetary breach continues in excess of *** days following notice from the party seeking termination, or
(2) such breach if a non-monetary breach continues in excess of *** days following notice from the party seeking termination provided, however, that the non-terminating party shall have a period in excess of *** days to cure any non-monetary
breach that cannot reasonably be cured within *** days, if the cure is commenced within such *** day period and with good faith and diligence is prosecuted to completion. 

B. Joint Termination. The Agreement may be terminated by the joint written agreement of the Company and the Group if any of the
following conditions shall occur: 
  

	 	(i)	if animal or human safety data and/or toxicological test results, in the reasonable opinion of the Company and the Group, support termination of the Study; or 

 

	 	(ii)	if the emergence of any adverse reaction or side effect with the Study Drug administered or the device employed in the Study is of such a magnitude or incidence in the reasonable opinion of the Company and the Group to
support termination. 

 C. Effect of Termination. As soon as reasonably possible following the effective date of the
termination of the Study, the Group shall stop entering Study Subjects into the Study and shall cease conducting procedures on Study Subjects already entered into the Protocol, to the extent medically and ethically permissible. In the event of a
termination under Section 8.A(ii), the Group shall, in its sole discretion, decide whether to stop entering Study Subjects into the Study; provided, however, that the Company agrees to continue supplying Study Drug as provided in the Agreement
after such a termination if the Group determines that such a requirement is reasonable under the circumstances of the termination, and that no such decision to continue the Study shall impose on the Company any obligation to perform services after
the effective date of said termination or to make payment for any such post-termination service(s) performed by the Group or others, except to the extent the Company has agreed to be responsible for the cost of distributing its Study Drug. 

D. Reimbursement of Expenses. Unless the Agreement provides otherwise, including without limitation a per-patient-enrolled payment rate
(in which event the Company shall be obligated to make full payment at the applicable rate, for all patients enrolled prior to the effective termination date), following any termination under this Section 8, there shall be an accounting
conducted by the Group to confirm the amount of payment to Group owed by the Company under the Agreement. This accounting shall be subject to verification and confirmation by the Company, which amount shall be calculated as the sum of: 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 10 

	 	(i)	A pro-rated amount of the payments set forth on Exhibit B, based on services rendered in the manner consistent with the Agreement, the Protocol and all monies properly expended therefor; and 

 

	 	(ii)	Reasonable non-cancelable obligations incurred for the Study by the Group prior to the effective date of the termination, including but not limited to those items set forth in the Agreement, which items the Company
agrees are reasonable and will be paid, provided, however, that the Company’s obligation hereunder (i.e, (i) and (ii) together) shall not exceed the total financial commitment of this Agreement. 

This accounting shall be subject to verification and confirmation by the Company which shall not be unreasonably withheld. Within *** days after receipt of
supporting documentation therefor, the Company will make payment to the Group for any amounts owed that have not been paid (or, conversely, the Group will refund any amounts paid but not owed). 

E. Obligations Continuing Following Termination. Termination of this Agreement under this Section 8 shall not affect the rights
and obligations of the parties accrued prior to the effective date of the termination. The rights and duties under Sections 2, 3, 4, 5, 6, 7, 8.C., 8.D., 8.E., 9, 10, 11, 18, and 22 survive the termination or expiration of this Agreement. 

 

	 	9.	NOTICES 

 All notices, requests, demands and other communications that this Agreement
requires or permits any party to give any other party shall be in writing and shall be given to such party at both of its addresses and/or facsimile numbers specified below: 
  

					
		 	If to Company:	  	Bob Goodenow
		 		  	Syndax Pharmaceuticals, Inc.
		 		  	400 Totten Pond Road, Suite 140
		 		  	Waltham, MA 02451
		 		  	Fax: (781) 419-1420
			
		 	If to Group:	  	Robert L. Comis, M.D.
		 		  	ECOG Group Chair’s Office
		 		  	1818 Market Street, Suite 1100
		 		  	Philadelphia, PA 19103-3602
		 		  	Fax: (267) 256-5291

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 11 

			
		 	With copies to:
		
		 	Donna Marinucci
		 	ECOG Group Chair’s Office
		 	1818 Market Street, Suite 1100
		 	Philadelphia, PA 19103-3602
		 	Fax: (267) 256-5291
		
		 	Mary Steele
		 	ECOG Coordinating Center Frontier Science
		 	900 Commonwealth Avenue
		 	Boston, MA 02215
		 	Fax: (617) 632-5414

 or at such other address or facsimile number as shall be designated by such party in a notice to the other party complying
with the terms of this Section. All notices, requests, demands and other communications provided for hereunder shall be effective (A) if given by mail on the third business day following deposit in the mails, with first class postage prepaid,
addressed as aforesaid, (B) if given by facsimile, when transmitted to the aforesaid facsimile number or (C) if given by personal delivery, including overnight delivery service, when delivered at the aforesaid address. 

 

	 	10.	ENTIRE AGREEMENT 

 This Agreement together with the Protocol represents the entire
understanding of the parties with respect to the subject matter hereof. In the event of any inconsistency between this Agreement and the Protocol, (A) the Protocol shall control with respect to any clinical matters and (B) this Agreement
shall control in all other respects. 
  

	 	11.	SEVERABILITY 

 The invalidity or unenforceability of any term or provision of this
Agreement shall not affect the validity or enforceability of any other term or provision hereof. 
  

	 	12.	INTEGRATION 

 The Protocol is incorporated into this Agreement by reference. 

 

	 	13.	ASSIGNMENT 

 Neither party hereto may assign, transfer or delegate any of its rights or
obligations under this Agreement without the written consent of the other party, which consent may not be unreasonably withheld; provided, however, without such consent either party may assign this 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 12 

 
Agreement in connection with the transfer or sale of all or substantially all of its assets or business or its merger or consolidation with another company. Either party may assign this Agreement
in whole or in part to any affiliate without consent of the other party. 
 This Agreement shall inure to the benefit of and be binding upon
each party signatory hereto, its successors and permitted assigns. No assignment shall relieve either party of the performance of any accrued obligation which such party may then have under this Agreement. 

 

	 	14.	INDEPENDENT CONTRACTOR 

 In the performances of all services hereunder, the Group shall
be deemed to be and shall be an independent contractor and, as such, shall not be entitled to any benefits applicable to employees of the Company. Neither party is authorized or empowered to act as agent for any purpose and shall not on behalf of
the other enter into any contract, warranty or representation as to any matter. Neither party shall be bound by the acts or conduct of the other. 
  

	 	15.	NO TRANSFER OF PROPRIETARY RIGHTS NOT SPECIFIED 

 It is agreed that neither the Company
nor the Group transfers to the other by operation of this Agreement any patent right, copyright right, or other proprietary right of either party, except as specifically set forth in this Agreement. 

 

	 	16.	CHANGES TO THE PROTOCOL 

 The Group shall not modify the Protocol or make any addendum to
the Protocol unless such modification or addendum is approved in advance by the NCI and the IRB; provided that administrative changes to the Protocol shall not require such approval. The NCI will provide notification to Company of changes to the
Protocol pursuant to its CRADA, and input from the Company will be received in response to notices received from NCI. If at a future date changes in a Protocol appears desirable to the Group (a “Group Change”) and increase the costs for
the Study and the Group wishes the Company to provide additional funding for the Study, the Group will submit to the Company for consideration the proposed Protocol amendment and a written estimate of all increased costs arising from the Group
Change. Such additional funding shall be provided as agreed to by the Group and the Company. If such changes have not been requested by the Group (a “Company Change”), and increase the costs for the Study, the Group will submit to the
Company a written estimate of all increased costs arising from the Company Change, and the Company shall pay such reasonable additional costs as required by the Group. All changes in the Protocol will be implemented immediately following NCI and IRB
approval. 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 13 

	 	17.	CONFORMANCE WITH LAW AND ACCEPTED PRACTICE 

 A. The Group shall perform the Study
in substantial conformance with generally accepted standards of good clinical practice, with the Protocol, and with all applicable local, state and federal laws and regulations governing the performance of clinical investigations including but not
limited to the Federal Food, Drug and Cosmetic Act and regulations of the FDA applicable to cooperative group clinical trials. 
 B.
The Group agrees to retain all records resulting from the Study for the time required by applicable federal regulations (for the Study, the Company will notify the Group of the FDA Application filing and approval status). 

 

	 	18.	WAIVER 

 No waiver of any term, provision or condition of this Agreement whether by
conduct or otherwise in any one or more instances shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition, or of any other term, provision or condition of this Agreement. 

 

	 	19.	FORCE MAJEURE 

 The Group or the Company shall not be liable for any failure to perform
as required by this Agreement, to the extent such failure to perform is due to circumstances reasonably beyond either party’s control, such as labor disturbances or labor disputes of any kind, accidents, failure of any governmental approval
required for full performance, civil disorders or commotions, acts of aggression, acts of God, explosions, failure of utilities, mechanical breakdowns, material shortages, disease, or other such occurrences. 

 

	 	20.	DEBARMENT AND DISQUALIFICATION 

 A. Neither the Group nor any person employed
thereby directly in the performance of the Study has been debarred under Section 306(a) or (b) of the Federal Food, Drug and Cosmetic Act and no debarred person will in the future be employed by the Group in connection with any work to be
performed for or on behalf of the Company which may later become part of any application for approval of a drug or biologic by the FDA. If at any time after execution of this Agreement, the Group becomes aware that the Group or any person employed
thereby is, or is in the process of being, debarred, the Group hereby certifies that the Group will properly notify the Company at once. 

B. To the Group’s reasonable knowledge, neither the investigator nor any sub-investigator of the Study shall be currently the
subject of a disqualification proceeding or have been disqualified by FDA as a clinical investigator pursuant to 21 CFR sec. 312.70, and neither an investigator nor any sub-investigator of the Study shall have entered into an agreement with FDA that
in any way restricts their ability to serve as clinical investigators. The 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 14 

 
Group shall notify the Company immediately upon its knowledge of any inquiry concerning, or the commencement of any such proceeding concerning, an investigator or any sub-investigator. 

 

	 	21.	AMENDMENTS 

 This Agreement may be extended, renewed or otherwise amended at any time
only by the mutual written consent of parties hereto. 
  

	 	22.	COUNTERPARTS 

 This Agreement may be executed in one or more counterparts, each of which
for all purposes shall be deemed to be an original, and all of which when taken together shall constitute but one and the same instrument. 

(signature pages follows) 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 15 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement, as of the Effective Date, by
proper persons thereunto duly authorized. 
  

							
	SYNDAX PHARMACEUTICALS, INC	 	EASTERN COOPERATIVE ONCOLOGY GROUP
				
	By:	 	 /s/ Robert Goodenow
	 	By:	 	 /s/ Robert L. Comis

		 	(signature)	 		 	 Robert L. Comis, M.D.
 Chair

				
	Name:	 	 Robert Goodenow
	 		 	

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 16 

 EXHIBIT A 

E2112 Scope of Work 
  

			
	Protocol Title:	 	A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Post-menopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
		
	Company:	 	Syndax Pharmaceuticals, Inc.

 *** 
 *** INDICATES EIGHT
PAGES OF MATERIAL THAT WERE OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 

  
 1 

 EXHIBIT B 

E2112 Budget & Payment Schedule 
  

	A.	Budget Details 

  

	1.	Budget 

 The budget for this project is $19,406,948 which is itemized as follows: 

 

			
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***
		
	 ***
	  	***

  

	2.	Invoicing and Payments 

 Company will make payments within *** of receipt of invoices from Group according to
the Payment Schedule herein. Payments will be made to as set forth in Section 1.B of the Agreement as follows: 
 ECOG Research and
Education Foundation, Inc. 
 Agent for ECOG Cooperative Oncology Group 

Attn: Donna Marinucci 
 1818
Market Street, Suite 1100 
 Philadelphia, PA 19103 

Group will send invoices to the following address: 

Jeannette Hasapidis 
 VP, Clinical
Operations 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

1 

 Syndax Pharmaceuticals, Inc. 

400 Totten Pond Road, Suite 110 

Waltham, MA 02451 
  

	B.	Payment Schedule 

 Group will submit invoices to Company in accordance with the following Payment
Schedule: 
 *** 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]